binding	O
sites	O
after	O
1	O
week	O
with	O
no	O
change	O
in	O
binding	O
affinity	O
.	O
No	O
changes	O
in	O
the	O
number	O
of	O
binding	O
sites	O
was	O
noted	O
before	O
1	O
week	O
and	O
the	O
diminished	O
number	O
persisted	O
for	O
1	O
week	O
after	O
discontinuation	O
of	O
glucocorticoid	O
treatment	O
.	O
Lymphocytes	O
from	O
hospitalized	O
patients	O
taking	O
40-60	O
mg	O
of	O
dexamethasone	O
daily	O
demonstrated	O
the	O
same	O
change	O
in	O
number	O
of	O
binding	O
sites	O
that	O
was	O
seen	O
in	O
normal	O
subjects	O
taking	O
1	O
mg	O
of	O
dexamethasone	O
.	O
When	O
binding	O
assays	O
were	O
carried	O
out	O
at	O
physiologic	O
temperature	O
there	O
was	O
the	O
same	O
decrease	O
in	O
number	O
of	O
binding	O
sites	O
after	O
dexamethasone	O
administration	O
,	O
and	O
in	O
addition	O
,	O
there	O
was	O
a	O
two-fold	O
increase	O
in	O
binding	O
affinity	O
.	O
Glucocorticoid	O
administration	O
results	O
in	O
a	O
time-dependent	O
decrease	O
in	O
the	O
number	O
of	O
lymphocyte	O
glucocorticoid	O
binding	O
sites	O
that	O
is	O
independent	O
of	O
the	O
type	O
of	O
glucocorticoid	O
administered	O
.	O
This	O
is	O
the	O
first	O
in	O
vivo	O
demonstration	O
that	O
glucocorticoids	O
modulate	O
their	O
own	O
receptors	O
in	O
man	O
.	O
Immunoglobulin	B-protein
localization	O
in	O
benign	O
and	O
malignant	O
lesions	O
of	O
the	O
human	O
mammary	O
gland	O
.	O
Using	O
direct	O
imunofluorescence	O
,	O
lesions	O
from	O
266	O
human	O
breast	O
specimens	O
were	O
studied	O
for	O
the	O
presence	O
of	O
IgA	O
,	O
IgM	B-protein
,	O
or	O
IgG	B-protein
localization	I-protein
.	O
The	O
lesions	O
included	O
benign	O
elements	O
from	O
66	O
subcutaneous	O
mastectomy	O
specimens	O
in	O
which	O
the	O
absence	O
of	O
simultaneous	O
breast	O
malignancy	O
was	O
documented	O
,	O
primary	O
breast	O
carcinomas	O
from	O
153	O
mastectomy	O
specimens	O
,	O
and	O
47	O
biopsies	O
containing	O
metastatic	O
breast	O
cancer	O
.	O
A	O
statistically	O
significant	O
association	O
of	O
IgA	O
and	O
IgM	B-protein
with	O
benign	O
lesions	O
was	O
contrasted	O
to	O
the	O
association	O
of	O
IgG	B-protein
with	O
malignant	O
lesions	O
.	O
In	O
both	O
primary	O
and	O
metastatic	O
lesions	O
,	O
IgG	B-protein
localization	I-protein
was	O
associated	O
with	O
estrogen-receptor-poor	O
primary	O
cancers	O
as	O
compared	O
with	O
estrogen-receptor-rich	O
primary	O
cancers	O
.	O
Among	O
primary	O
breast	O
cancer	O
patients	O
,	O
IgG	B-protein
localization	I-protein
in	O
the	O
tumor	O
correlated	O
with	O
relative	O
lymphopenia	O
.	O
A	O
shorter	O
disease-free	O
interval	O
was	O
noted	O
in	O
association	O
with	O
IgG	B-protein
localization	I-protein
among	O
the	O
metastatic	O
breast	O
lesions	O
.	O
No	O
statistically	O
significant	O
association	O
between	O
stage	O
of	O
disease	O
and	O
immunoglobulin	O
presence	O
was	O
demonstrable	O
.	O
Moderate-to-severe	O
intraductal	O
epithelial	O
hyperplasias	O
were	O
more	O
often	O
associated	O
with	O
immunoglobulin	O
G	O
localization	O
that	O
were	O
other	O
benign	O
lesions	O
Correlation	O
of	O
steroid	B-protein
receptors	I-protein
with	O
histologic	O
differentiation	O
in	O
mammary	O
carcinoma	O
.	O
A	O
Singapore	O
experience	O
.	O
Cancer	O
of	O
the	O
breast	O
is	O
the	O
most	O
common	O
tumor	O
in	O
females	O
in	O
Singapore	O
,	O
with	O
the	O
rate	O
of	O
20.7	O
per	O
100	O
,	O
000	O
per	O
year	O
(	O
1977	O
estimate	O
)	O
,	O
which	O
is	O
predicted	O
to	O
increase	O
to	O
29.8	O
per	O
100	O
,	O
000	O
women	O
per	O
year	O
by	O
1995	O
.	O
A	O
detailed	O
histopathologic	O
review	O
of	O
50	O
primary	O
breast	O
cancer	O
tumors	O
analyzed	O
for	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
level	O
was	O
carried	O
out	O
and	O
a	O
variety	O
of	O
morphologic	O
features	O
correlated	O
with	O
ER	B-protein
results	O
to	O
identify	O
any	O
factors	O
that	O
will	O
improve	O
the	O
management	O
and	O
prognosis	O
for	O
breast	O
cancer	O
.	O
Cytosol	O
was	O
incubated	O
with	O
3H-estradiol	O
in	O
the	O
presence	O
and	O
absence	O
of	O
cold	O
diethylstilbestrol	O
,	O
and	O
bound	O
and	O
free	O
hormone	O
were	O
separated	O
by	O
Dextran-coated	O
charcoal	O
method	O
.	O
Tumors	O
binding	O
more	O
than	O
5	O
fmol/mg	O
cytosol	O
protein	O
were	O
classified	O
as	O
ER	B-protein
-positive	O
.	O
Progesterone	B-protein
receptor	I-protein
(	O
PR	B-protein
)	O
level	O
was	O
analyzed	O
in	O
some	O
specimens	O
with	O
the	O
use	O
of	O
a	O
similar	O
method	O
.	O
Most	O
of	O
the	O
patients	O
were	O
Chinese	O
(	O
90	O
%	O
)	O
.	O
Three	O
patients	O
were	O
Malays	O
,	O
one	O
was	O
Indian	O
,	O
and	O
one	O
was	O
European	O
in	O
this	O
series	O
.	O
Results	O
indicated	O
that	O
there	O
was	O
strong	O
correlation	O
between	O
ER	O
level	O
,	O
age	O
,	O
and	O
histologic	O
grade	O
of	O
the	O
tumors	O
.	O
No	O
correlation	O
existed	O
between	O
absence	O
or	O
presence	O
of	O
lymph	O
node	O
metastases	O
and	O
ER	B-protein
.	O
Although	O
there	O
was	O
a	O
trend	O
for	O
ER	B-protein
-positive	O
tumors	O
to	O
have	O
a	O
low-grade	O
lymphocytic	O
infiltration	O
,	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O
Mononuclear	O
cells	O
infiltrating	O
human	O
mammary	O
carcinomas	O
:	O
immunohistochemical	O
analysis	O
with	O
monoclonal	B-protein
antibodies	I-protein
.	O
Breast	O
carcinomas	O
were	O
examined	O
by	O
the	O
immunoperoxidase	O
technique	O
using	O
antisera	O
specific	O
for	O
lymphocyte	O
subsets	O
,	O
monocytes	O
,	O
NK	O
cells	O
and	O
major	B-protein
histocompatibility	I-protein
antigens	I-protein
(	O
HLA-A	O
,	O
-B	O
,	O
-C	O
;	O
Ia-like	O
)	O
.	O
Sixty-four	O
per	O
cent	O
of	O
the	O
patients	O
had	O
a	O
moderate	O
or	O
strong	O
mononuclear	O
cell	O
infiltration	O
,	O
77	O
%	O
of	O
the	O
patients	O
without	O
mononuclear	O
cell	O
infiltration	O
had	O
receptors	O
for	O
estrogens	O
as	O
compared	O
to	O
51	O
%	O
of	O
the	O
patients	O
with	O
infiltration	O
.	O
The	O
majority	O
of	O
the	O
infiltrating	O
mononuclear	O
cells	O
were	O
T	O
cells	O
;	O
generally	O
the	O
OKT8	O
cells	O
were	O
predominant	O
.	O
The	O
Leu	O
3A/OKT8	O
cell	O
ratio	O
was	O
not	O
related	O
to	O
histological	O
type	O
,	O
tumor	O
size	O
,	O
age	O
of	O
the	O
patient	O
or	O
presence	O
of	O
metastases	O
.	O
Some	O
of	O
the	O
T	O
cells	O
had	O
the	O
Ia	B-protein
antigen	I-protein
and	O
were	O
thus	O
probably	O
activated	O
.	O
The	O
B	O
cells	O
were	O
either	O
absent	O
or	O
less	O
numerous	O
than	O
the	O
T	O
cells	O
.	O
There	O
was	O
no	O
relation	O
between	O
their	O
distribution	O
and	O
the	O
various	O
parameters	O
studied	O
.	O
A	O
few	O
monocytes	O
were	O
heterogeneous	O
according	O
to	O
their	O
markers	O
(	O
OKM	O
I	O
and	O
acid	B-protein
phosphatase	I-protein
)	O
.	O
In	O
6	O
cases	O
only	O
there	O
was	O
a	O
strong	O
infiltration	O
of	O
mononuclear	O
cells	O
positive	O
for	O
acid	B-protein
phosphatase	I-protein
.	O
The	O
number	O
of	O
the	O
natural	O
killer	O
cells	O
was	O
also	O
low	O
.	O
Only	O
a	O
few	O
mononuclear	O
infiltrating	O
cells	O
had	O
receptors	O
for	O
transferrin	O
.	O
There	O
was	O
a	O
positive	O
correlation	O
between	O
the	O
inflammatory	O
infiltration	O
and	O
the	O
presence	O
of	O
HLA	B-protein
class-I	I-protein
antigens	I-protein
on	O
tumor	O
cell	O
s	O
.	O
Some	O
of	O
the	O
antisera	O
specific	O
for	O
lymphocyte	O
subsets	O
also	O
stained	O
the	O
breast	O
carcinoma	O
cells	O
.	O
The	O
great	O
variations	O
in	O
the	O
subsets	O
of	O
mononuclear	O
cells	O
in	O
breast	O
carcinomas	O
may	O
correspond	O
to	O
various	O
systems	O
of	O
defense	O
against	O
neoplasm	O
.	O
A	O
case	O
of	O
male	O
pseudohermaphroditism	O
with	O
normal	O
androgen	O
receptor	O
binding	O
and	O
47	O
,	O
XYY	O
karyotype	O
.	O
A	O
case	O
of	O
male	O
pseudohermaphroditism	O
with	O
47	O
,	O
XYY	O
karyotype	O
in	O
blood	O
and	O
cutaneous	O
fibroblasts	O
is	O
described	O
.	O
The	O
plasma	O
testosterone	O
response	O
to	O
HCG	O
stimulation	O
was	O
slightly	O
below	O
the	O
normal	O
range	O
on	O
two	O
occasions	O
suggesting	O
a	O
deficit	O
of	O
gonadal	O
function	O
.	O
A	O
study	O
of	O
the	O
receptors	O
for	O
dihydrotestosterone	O
in	O
fibroblasts	O
of	O
genital	O
and	O
nongenital	O
skin	O
showed	O
a	O
normal	O
concentration	O
of	O
receptors	O
in	O
genital	O
skin	O
;	O
5-alpha-reductase	O
activity	O
in	O
fibroblasts	O
of	O
the	O
genital	O
skin	O
was	O
low	O
,	O
but	O
the	O
plasma	O
relationship	O
testosterone/dihydrotestosterone	O
under	O
HCG	O
stimulation	O
was	O
normal	O
.	O
The	O
diagnostic	O
possibility	O
of	O
a	O
complete	O
testicular	O
feminization	O
syndrome	O
with	O
normal	B-protein
receptors	I-protein
for	O
dihydrotestosterone	O
is	O
commented	O
on	O
.	O
1	O
,	O
25-Dihydroxyvitamin	O
D3	O
inhibits	O
antigen-induced	O
T	O
cell	O
activation	O
.	O
The	O
proliferative	O
response	O
of	O
murine	O
spleen	O
and	O
thymus	O
cells	O
to	O
antigen	O
but	O
not	O
to	O
lectin	O
was	O
inhibited	O
by	O
the	O
active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
.	O
To	O
directly	O
examine	O
the	O
effect	O
of	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
on	O
T	O
cell	O
activation	O
in	O
the	O
absence	O
of	O
other	O
complicating	O
interactions	O
,	O
we	O
utilized	O
a	O
panel	O
of	O
cloned	O
Ia-restricted	O
T	O
cell	O
hybridomas	O
that	O
secrete	O
IL	B-protein
2	I-protein
on	O
activation	O
by	O
cloned	O
Ia-bearing	O
stimulator	O
cells	O
(	O
TA3	O
)	O
or	O
when	O
stimulated	O
by	O
mitogen	O
.	O
Physiologic	O
concentrations	O
of	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
(	O
0.01	O
to	O
0.1	O
nm	O
)	O
inhibited	O
the	O
antigen-induced	O
secretion	O
of	O
IL	B-protein
2	I-protein
by	O
several	O
of	O
these	O
T	O
cell	O
hybridomas	O
.	O
This	O
inhibition	O
was	O
dependent	O
on	O
the	O
concentration	O
of	O
the	O
free	O
hormone	O
and	O
could	O
be	O
overcome	O
by	O
increasing	O
the	O
number	O
of	O
Ia-bearing	O
stimulator	O
cells	O
used	O
.	O
Pretreatment	O
of	O
the	O
T	O
hybridoma	O
but	O
not	O
the	O
TA3	O
stimulator	O
cell	O
with	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
resulted	O
in	O
inhibition	O
of	O
activation	O
.	O
These	O
results	O
are	O
consistent	O
with	O
the	O
finding	O
that	O
specific	B-protein
1	I-protein
,	I-protein
25-	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
are	O
present	O
on	O
the	O
T	O
cell	O
hybridomas	O
but	O
are	O
lacking	O
in	O
TA3	O
cells	O
.	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
failed	O
,	O
however	O
,	O
to	O
inhibit	O
the	O
activation	O
of	O
the	O
T	O
cell	O
hybridomas	O
by	O
lectin	B-protein
or	O
by	O
an	O
anti-Thy-1	B-protein
antibody	I-protein
.	O
These	O
findings	O
suggest	O
that	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
may	O
be	O
interfering	O
with	O
early	O
events	O
of	O
antigen-induced	O
T	O
cell	O
activation	O
,	O
perhaps	O
by	O
hindering	O
T	O
cell	O
recognition	O
of	O
the	O
relevant	O
antigen	O
on	O
stimulator	O
cell	O
surfaces	O
.	O
This	O
system	O
should	O
prove	O
useful	O
in	O
studying	O
the	O
molecular	O
mechanisms	O
by	O
which	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
acts	O
to	O
inhibit	O
T	O
cell	O
activation	O
and	O
subsequent	B-protein
IL	I-protein
2	I-protein
production	O
.	O
Glucocorticoid	B-protein
receptors	I-protein
and	O
steroid	O
sensitivity	O
in	O
normal	O
and	O
neoplastic	O
human	O
lymphoid	O
tissues	O
:	O
a	O
review	O
.	O
The	O
determination	O
of	O
estrogen	B-protein
and	I-protein
progesterone	I-protein
receptors	I-protein
in	O
breast	O
cancer	O
has	O
been	O
shown	O
to	O
be	O
useful	O
in	O
predicting	O
the	O
response	O
to	O
endocrine	O
therapy	O
.	O
Given	O
their	O
well-known	O
inhibitory	O
effects	O
on	O
lymphoid	O
tissue	O
,	O
glucocorticoids	O
have	O
been	O
used	O
widely	O
in	O
the	O
treatment	O
of	O
leukemia	O
.	O
Given	O
these	O
facts	O
,	O
over	O
the	O
last	O
10	O
years	O
,	O
several	O
investigators	O
have	O
measured	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
normal	O
and	O
neoplastic	O
lymphoid	O
tissue	O
to	O
see	O
whether	O
their	O
number	O
correlated	O
with	O
glucocorticoid	O
responsiveness	O
in	O
vitro	O
or	O
in	O
vivo	O
.	O
No	O
clear	O
correlation	O
could	O
be	O
established	O
between	O
the	O
level	O
of	O
glucocorticoid	B-protein
receptor	I-protein
and	O
the	O
in	O
vitro	O
action	O
of	O
steroids	O
in	O
normal	O
and	O
neoplastic	O
lymphoid	O
tissue	O
.	O
In	O
contrast	O
,	O
attempts	O
to	O
correlate	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
in	O
acute	O
lymphocytic	O
leukemia	O
to	O
in	O
vivo	O
steroid	O
responsiveness	O
and	O
immunological	O
type	O
using	O
the	O
whole-cell-binding	O
assay	O
for	O
receptor	O
determination	O
and	O
selecting	O
the	O
patients	O
according	O
to	O
age	O
and	O
immunological	O
criteria	O
have	O
been	O
more	O
successful	O
.	O
[	O
Glucocorticoid	B-protein
receptors	I-protein
in	O
normal	O
human	O
lymphocytes	O
]	O
Glucocorticoid	O
(	O
GC	O
)	O
receptors	O
were	O
studied	O
in	O
intact	O
lymphocytes	O
from	O
11	O
donors	O
.	O
GC	O
binding	O
parameters	O
were	O
found	O
to	O
be	O
highly	O
reproducible	O
in	O
repeated	O
experiments	O
with	O
lymphocytes	O
.	O
It	O
was	O
shown	O
that	O
GC	B-protein
receptors	I-protein
in	O
donors	O
'	O
lymphocytes	O
could	O
be	O
distributed	O
into	O
two	O
different	O
classes	O
similarly	O
to	O
the	O
pattern	O
seen	O
in	O
skin	O
fibroblasts	O
.	O
Human	O
lymphocytes	O
are	O
an	O
adequate	O
object	O
for	O
studying	O
genetically	O
determined	O
variability	O
of	O
GC	B-protein
receptors	I-protein
and	O
its	O
clinical	O
importance	O
.	O
Specific	O
estrogen	O
binding	O
sites	O
in	O
human	O
lymphoid	O
cells	O
and	O
thymic	O
cells	O
.	O
The	O
binding	O
of	O
estrogen	O
in	O
preparations	O
of	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
as	O
well	O
as	O
by	O
splenic	O
and	O
thymic	O
cells	O
is	O
demonstrated	O
by	O
three	O
different	O
approaches	O
(	O
Dextran-coated	O
charcoal	O
method	O
,	O
whole	O
cell	O
assay	O
,	O
and	O
gel	O
filtration	O
on	O
a	O
sepharose	O
4B	O
column	O
)	O
.	O
Scatchard	O
's	O
analysis	O
of	O
[	O
3H	O
]	O
-moxestrol	O
(	O
R2858	O
)	O
and	O
[	O
3H	O
]	O
-estradiol	O
binding	O
proves	O
the	O
existence	O
of	O
a	O
single	O
class	O
of	O
receptor	O
sites	O
having	O
a	O
dissociation	O
constant	O
of	O
0.18-2.4	O
X	O
10	O
(	O
-9	O
)	O
M	O
.	O
Physicochemical	O
properties	O
of	O
the	O
binder	O
,	O
including	O
binding	O
capacity	O
and	O
steroid	O
specificity	O
,	O
are	O
quite	O
similar	O
to	O
those	O
reported	O
for	O
the	O
thymus	O
of	O
small	O
mammalian	O
species	O
or	O
human	O
thymoma	O
.	O
Administration	O
of	O
fibroblast	B-protein
interferon	I-protein
to	O
patients	O
with	O
advanced	O
breast	O
cancer	O
:	O
possible	O
effects	O
on	O
skin	O
metastasis	O
and	O
on	O
hormone	B-protein
receptors	I-protein
.	O
Eleven	O
patients	O
with	O
metastasized	O
breast	O
cancer	O
received	O
8	O
intramuscular	O
injections	O
of	O
6	O
x	O
10	O
(	O
6	O
)	O
units	O
of	O
human	B-protein
fibroblast	I-protein
interferon	I-protein
over	O
a	O
period	O
of	O
40	O
days	O
.	O
The	O
injections	O
did	O
not	O
cause	O
local	O
irritation	O
or	O
inflammation	O
.	O
Fever	O
occurred	O
in	O
only	O
1	O
of	O
the	O
11	O
patients	O
.	O
Although	O
several	O
types	O
of	O
metastases	O
were	O
monitored	O
,	O
only	O
skin	O
nodules	O
consistently	O
(	O
10	O
out	O
of	O
11	O
patients	O
)	O
exhibited	O
changes	O
that	O
were	O
suggestive	O
of	O
a	O
therapeutic	O
effect	O
of	O
the	O
treatment	O
regimen	O
:	O
either	O
a	O
simple	O
decrease	O
in	O
size	O
of	O
some	O
nodules	O
or	O
central	O
necrosis	O
accompanied	O
by	O
an	O
inflammatory	O
reaction	O
.	O
NK-activity	O
of	O
peripheral	O
blood	O
leukocytes	O
was	O
significantly	O
increased	O
after	O
administration	O
of	O
the	O
first	O
dose	O
;	O
the	O
effect	O
of	O
subsequent	O
injections	O
was	O
less	O
clear	O
.	O
Receptors	O
for	O
estrogens	O
and	O
progestogens	O
were	O
increased	O
in	O
the	O
tumor	O
biopsies	O
of	O
2	O
out	O
of	O
2	O
and	O
5	O
out	O
of	O
6	O
patients	O
tested	O
respectively	O
.	O
Decreased	O
glucocorticoid	B-protein
receptor	I-protein
binding	O
in	O
adrenal	O
insufficiency	O
.	O
To	O
examine	O
the	O
effect	O
of	O
glucocorticoid	O
deficiency	O
on	O
the	O
glucocorticoid	B-protein
receptor	I-protein
,	O
we	O
examine	O
the	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	O
to	O
lymphocytes	O
in	O
normal	O
subjects	O
and	O
patients	O
with	O
adrenal	O
insufficiency	O
before	O
and	O
after	O
glucocorticoid	O
replacement	O
therapy	O
.	O
Using	O
a	O
whole	O
cell	O
competitive	O
binding	O
assay	O
,	O
normal	O
human	O
lymphocytes	O
had	O
5977	O
+/-	O
1487	O
(	O
mean	O
+/-	O
SD	O
)	O
binding	O
sites/cell	O
and	O
a	O
dissociation	O
constant	O
of	O
10	O
+/-	O
2	O
nM	O
.	O
Lymphocytes	O
from	O
patients	O
with	O
untreated	O
adrenal	O
insufficiency	O
had	O
fewer	O
binding	O
sites	O
(	O
3364	O
+/-322	O
)	O
and	O
a	O
2-fold	O
increase	O
in	O
binding	O
affinity	O
(	O
5.4	O
+/-	O
0.9	O
mM	O
)	O
.	O
The	O
administration	O
of	O
conventional	O
replacement	O
doses	O
of	O
cortisone	O
acetate	O
for	O
6	O
months	O
caused	O
no	O
change	O
in	O
receptor	O
number	O
,	O
but	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
binding	O
affinity	O
toward	O
normal	O
.	O
After	O
long	O
term	O
glucocorticoid	O
replacement	O
therapy	O
,	O
binding	O
parameters	O
were	O
similar	O
to	O
those	O
in	O
patients	O
before	O
treatment	O
.	O
The	O
physiological	O
implications	O
of	O
the	O
decreased	O
receptor	O
number	O
and	O
increased	O
binding	O
affinity	O
in	O
adrenal	O
insufficiency	O
remain	O
to	O
be	O
elucidated	O
.	O
Glucocorticoid	B-protein
receptor	I-protein
concentrations	O
and	O
terminal	O
transferase	O
activity	O
as	O
indicators	O
of	O
prognosis	O
in	O
acute	O
non-lymphocytic	O
leukaemia	O
.	O
Activity	O
of	O
terminal	O
deoxynucleotidyl	O
transferase	O
(	O
TdT	O
)	O
,	O
adenosine	O
deaminase	O
,	O
and	O
5'nucleotidase	O
and	O
the	O
cellular	O
concentration	O
of	O
glucocorticoid	O
(	O
dexamethasone	O
)	O
receptor	O
were	O
determined	O
in	O
25	O
patients	O
with	O
acute	O
non-lymphocytic	O
leukaemia	O
.	O
All	O
patients	O
were	O
treated	O
according	O
to	O
a	O
common	O
protocol	O
.	O
Increased	O
activity	O
of	O
TdT	O
(	O
greater	O
than	O
0.1	O
unit/microgram	O
DNA	O
)	O
was	O
found	O
in	O
11	O
patients	O
.	O
This	O
group	O
of	O
patients	O
was	O
shown	O
to	O
have	O
higher	O
remission	O
and	O
survival	O
rates	O
(	O
p	O
=	O
0.06	O
)	O
compared	O
with	O
patients	O
with	O
low	O
activity	O
of	O
TdT	O
.	O
The	O
glucocorticoid	B-protein
receptor	I-protein
concentration	O
of	O
the	O
leukaemic	O
blast	O
cells	O
ranged	O
from	O
0	O
to	O
0.94	O
fmol/microgram	O
DNA	O
.	O
Thirteen	O
patients	O
had	O
blast	O
cells	O
with	O
a	O
glucocorticoid	B-protein
receptor	I-protein
concentration	O
over	O
0.22	O
fmol/microgram	O
DNA	O
.	O
These	O
patients	O
had	O
significantly	O
increased	O
remission	O
and	O
survival	O
rates	O
(	O
p	O
=	O
0.006	O
)	O
compared	O
with	O
those	O
with	O
a	O
low	O
receptor	O
concentration	O
.	O
This	O
finding	O
can	O
not	O
be	O
explained	O
by	O
a	O
difference	O
in	O
sensitivity	O
to	O
glucocorticoids	O
since	O
these	O
were	O
not	O
used	O
as	O
therapeutic	O
agents	O
.	O
Adenosine	O
deaminase	O
and	O
5'nucleotidase	O
activities	O
both	O
varied	O
within	O
two	O
orders	O
of	O
magnitude	O
.	O
No	O
correlation	O
could	O
be	O
found	O
between	O
activities	O
of	O
these	O
enzymes	O
and	O
remission	O
or	O
survival	O
rate	O
.	O
These	O
results	O
show	O
that	O
measurements	O
of	O
TdT	O
activity	O
and	O
the	O
glucocorticoid	B-protein
receptor	I-protein
concentration	O
yield	O
valuable	O
prognostic	O
information	O
in	O
acute	O
non-lymphocytic	O
leukaemia	O
[	O
3H	O
]	O
cortivazol	O
:	O
a	O
unique	O
high	O
affinity	O
ligand	O
for	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O
Cortivazol	O
(	O
CVZ	O
)	O
and	O
deacylcortivazol	O
(	O
DAC	O
)	O
are	O
pyrazolosteroids	O
with	O
potent	O
glucocorticoid	O
activity	O
.	O
In	O
previous	O
work	O
we	O
showed	O
that	O
DAC	B-protein
is	O
40-fold	O
more	O
potent	O
than	O
dexamethasone	O
(	O
DEX	O
)	O
in	O
lysing	O
leukemic	O
lymphoblasts	O
.	O
To	O
assess	O
the	O
interaction	O
between	O
these	O
atypical	O
steroids	O
and	O
the	O
glucocorticoid	B-protein
receptor	I-protein
,	O
we	O
examined	O
the	O
binding	O
of	O
[	O
3H	O
]	O
CVZ	O
to	O
cytosol	O
from	O
glucocorticoid-sensitive	O
and	O
-resistant	O
variants	O
of	O
the	O
human	O
leukemic	O
cell	O
line	O
CEM	O
C7	O
.	O
In	O
glucocorticoid-sensitive	O
cells	O
[	O
3H	O
]	O
CVZ	O
causes	O
a	O
2-fold	O
induction	O
of	O
glutamine	B-protein
synthetase	I-protein
and	O
binds	O
to	O
a	O
protein	O
in	O
the	O
4.6	O
S	O
region	O
of	O
high	O
salt	O
sucrose	O
gradients	O
.	O
On	O
DEAE-cellulose	O
chromatography	O
,	O
[	O
3H	O
]	O
CVZ-receptor	O
complexes	O
show	O
a	O
shift	O
from	O
high	O
(	O
0.25	O
M	O
KP	O
)	O
to	O
low	O
salt	O
(	O
0.09	O
M	O
KP	O
)	O
eluting	O
forms	O
upon	O
activation	O
.	O
CVZ	O
competes	O
for	O
a	O
97	O
,	O
000-dalton	O
protein	O
labeled	O
by	O
[	O
3H	O
]	O
dexamethasone	O
mesylate	O
.	O
Scatchard	O
analysis	O
of	O
the	O
binding	O
of	O
[	O
3H	O
]	O
CVZ	O
in	O
glucocorticoid-sensitive	O
cells	O
revealed	O
a	O
curvilinear	O
plot	O
which	O
resolved	O
into	O
high	O
(	O
0.4	O
nM	O
)	O
and	O
low	O
(	O
11	O
nM	O
)	O
affinity	O
components	O
.	O
The	O
receptor	O
concentration	O
of	O
the	O
low	O
affinity	O
site	O
(	O
0.30	O
pmol/mg	O
protein	O
)	O
was	O
approximately	O
twice	O
that	O
of	O
the	O
high	O
affinity	O
site	O
(	O
0.14	O
pmol/mg	O
protein	O
)	O
.	O
Dissociation	O
experiments	O
with	O
dilution	O
and/or	O
excess	O
unlabeled	O
CVZ	O
supported	O
the	O
presence	O
of	O
independent	O
sites	O
.	O
In	O
contrast	O
,	O
the	O
binding	O
of	O
[	O
3H	O
]	O
DEX	O
to	O
C7	O
cytosol	O
revealed	O
a	O
single	O
class	O
of	O
binding	O
sites	O
(	O
Kd	O
=	O
1.9	O
nM	O
;	O
receptor	O
concentration	O
,	O
0.46	O
pmol/mg	O
protein	O
)	O
.	O
Examination	O
of	O
the	O
binding	O
of	O
[	O
3H	O
]	O
CVZ	O
using	O
10	O
(	O
-5	O
)	O
M	O
DEX	O
as	O
the	O
competing	O
ligand	O
showed	O
that	O
DEX	O
binds	O
only	O
to	O
the	O
low	O
affinity	O
site	O
detected	O
by	O
[	O
3H	O
]	O
CVZ	O
.	O
In	O
cytosol	O
from	O
a	O
glucocorticoid-resistant	O
cell	O
line	O
with	O
virtually	O
no	O
[	O
3H	O
]	O
DEX	O
binding	O
,	O
[	O
3H	O
]	O
CVZ	O
detected	O
a	O
single	O
high	O
affinity	O
binding	O
site	O
that	O
was	O
similar	O
in	O
dissociation	O
constant	O
(	O
0.8	O
nM	O
)	O
and	O
receptor	O
concentration	O
(	O
0.13	O
pmol/mg	O
protein	O
)	O
to	O
the	O
high	O
affinity	O
site	O
detected	O
in	O
the	O
glucocorticoid-sensitive	O
cell	O
line	O
C7	O
.	O
A	O
controlled	O
pore	O
glass	O
bead	O
assay	O
for	O
the	O
measurement	O
of	O
cytoplasmic	B-protein
and	I-protein
nuclear	I-protein
glucocorticoid	I-protein
receptors	I-protein
.	O
An	O
assay	O
for	O
the	O
quantitation	O
of	O
cytoplasmic	B-protein
and	I-protein
nuclear	I-protein
glucocorticoid	I-protein
receptors	I-protein
in	O
lymphoid	O
tissue	O
has	O
been	O
developed	O
using	O
controlled	O
pore	O
glass	O
(	O
CPG	O
)	O
beads	O
.	O
Soluble	B-protein
receptor	I-protein
--	I-protein
3H-steroid	I-protein
complex	I-protein
(	O
cytosol	O
or	O
nuclear	O
extract	O
)	O
is	O
adsorbed	O
quantitatively	O
within	O
the	O
crevasses	O
of	O
porous	O
glass	O
beads	O
.	O
Excess	O
labeled	O
steroid	O
as	O
well	O
as	O
most	O
non-specifically	O
bound	O
steroid	O
is	O
easily	O
washed	O
away	O
,	O
leaving	O
the	O
hormone-receptor	B-protein
complex	I-protein
retained	O
by	O
the	O
beads	O
.	O
Bound	O
3H-steroid	O
is	O
eluted	O
with	O
ethanol	O
and	O
measured	O
for	O
radioactivity	O
.	O
This	O
procedure	O
which	O
is	O
simple	O
,	O
rapid	O
,	O
and	O
highly	O
reproducible	O
is	O
carried	O
out	O
using	O
frozen	O
samples	O
(	O
stable	O
for	O
many	O
months	O
)	O
containing	O
as	O
few	O
as	O
1	O
X	O
10	O
(	O
7	O
)	O
cells	O
.	O
A	O
comparison	O
of	O
the	O
CPG	O
assay	O
to	O
dextran	O
coated	O
charcoal	O
and	O
a	O
whole	O
cell	O
assay	O
demonstrates	O
that	O
CPG	B-protein
and	O
dextran	O
coated	O
charcoal	O
give	O
equivalent	O
measurements	O
of	O
cytosolic	B-protein
receptor	I-protein
concentration	O
,	O
while	O
the	O
CPG	O
and	O
whole	O
cell	O
assays	O
provide	O
equivalent	O
values	O
for	O
total	B-protein
receptor	I-protein
content	O
.	O
Plasmacytoid	O
blast	O
crisis	O
in	O
B-cell	O
chronic	O
lymphocytic	O
leukemia	O
:	O
effect	O
of	O
estradiol	O
on	O
growth	O
and	O
differentiation	O
in	O
vitro	O
.	O
Evolution	O
of	O
a	O
case	O
of	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
into	O
blast	O
crisis	O
was	O
found	O
to	O
be	O
characterized	O
by	O
three	O
unusual	O
features	O
(	O
1	O
)	O
the	O
phenotype	O
of	O
the	O
emerging	O
blast	O
cells	O
was	O
that	O
of	O
pre-plasmacytoid	O
cells	O
as	O
shown	O
by	O
plasma	O
cell	O
morphology	O
and	O
an	O
immunological	O
phenotype	O
corresponding	O
partially	O
with	O
CLL-	O
or	O
intermediate	O
B-cells	O
,	O
partially	O
with	O
plasma	O
cells	O
(	O
terminal	O
transferase	O
-	O
,	O
common	O
acute	O
lymphocytic	O
leukemia	O
antigen	O
-	O
,	O
Ia+	O
,	O
surface	B-protein
immunoglobulin	I-protein
heavy	I-protein
chains	I-protein
-	O
,	O
surface	B-protein
kappa	I-protein
light	I-protein
chains	I-protein
+	O
,	O
intracytoplasmic	O
immunoglobulin	O
A+	O
and	O
G+	O
,	O
BA-1+	O
,	O
polyclonal	O
gammaglobulin	O
production	O
)	O
;	O
(	O
2	O
)	O
cytogenetic	O
analysis	O
of	O
spontaneous	O
metaphases	O
revealed	O
that	O
in	O
addition	O
to	O
the	O
typical	O
CLL	O
abnormality	O
,	O
trisomy	O
12	O
,	O
in	O
all	O
of	O
the	O
cells	O
,	O
an	O
additional	O
translocation	O
between	O
chromosomes	O
14	O
and	O
17	O
was	O
present	O
in	O
40	O
%	O
with	O
a	O
presumptive	O
breakpoint	O
on	O
chromosome	O
14	O
(	O
q12-3	O
)	O
never	O
described	O
before	O
(	O
commonly	O
q32	O
)	O
and	O
(	O
3	O
)	O
the	O
progression	O
of	O
the	O
disease	O
was	O
associated	O
with	O
a	O
striking	O
increase	O
in	O
the	O
expression	O
by	O
the	O
transformed	O
cells	O
of	O
specific	O
binding	O
sites	O
for	O
estradiol	O
(	O
E2	O
)	O
due	O
to	O
an	O
actual	O
increase	O
in	O
total	O
cellular	B-protein
receptor	I-protein
proteins	I-protein
and	O
not	O
to	O
a	O
change	O
in	O
receptor	O
affinity	O
for	O
E2	O
.	O
The	O
functional	O
status	O
of	O
the	O
steroid	B-protein
receptors	I-protein
was	O
confirmed	O
by	O
nuclear	O
transfer	O
of	O
the	O
cytoplasmic	B-protein
hormone-receptor	I-protein
complex	I-protein
upon	O
temperature	O
activation	O
.	O
Since	O
the	O
rise	O
in	O
E2-receptor	O
display	O
paralleled	O
a	O
large	O
increase	O
in	O
the	O
proliferative	O
activity	O
of	O
the	O
cells	O
as	O
well	O
as	O
a	O
change	O
in	O
their	O
maturation	O
status	O
the	O
question	O
was	O
raised	O
as	O
to	O
whether	O
the	O
E2-receptor	O
should	O
be	O
considered	O
as	O
a	O
physiological	O
marker	O
of	O
growth	O
rate	O
or	O
of	O
cellular	O
differentiation	O
.	O
Exposure	O
of	O
the	O
patient	O
's	O
blast	O
cells	O
to	O
E2	O
in	O
vitro	O
resulted	O
in	O
cessation	O
of	O
cell	O
growth	O
following	O
at	O
least	O
one	O
mitosis	O
after	O
addition	O
of	O
the	O
inducer	O
as	O
seen	O
from	O
the	O
replacement	O
of	O
the	O
large	O
blasts	O
by	O
small	O
CLL-like	O
cells	O
without	O
definite	O
signs	O
of	O
alteration	O
of	O
the	O
differentiation	O
status	O
.	O
This	O
suggests	O
the	O
association	O
of	O
E2-receptor	O
expression	O
with	O
control	O
of	O
growth	O
rather	O
than	O
cell	O
maturation	O
.	O
Multiple	O
forms	O
and	O
fragments	O
of	O
cytosolic	B-protein
glucocorticoid	I-protein
receptors	I-protein
from	O
human	O
leukemic	O
cells	O
and	O
normal	O
lymphocytes	O
.	O
Therapy	O
with	O
glucocorticoids	O
is	O
generally	O
more	O
effective	O
in	O
acute	O
lymphoblastic	O
leukemia	O
than	O
in	O
other	O
types	O
of	O
human	O
leukemia	O
.	O
Previous	O
studies	O
,	O
however	O
,	O
have	O
not	O
revealed	O
any	O
consistent	O
relationship	O
between	O
clinical	O
responsiveness	O
and	O
the	O
cellular	O
or	O
cytosolic	O
concentration	O
of	O
glucocorticoid-binding	O
sites	O
.	O
The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
determine	O
whether	O
there	O
are	O
intrinsic	O
structural	O
differences	O
among	O
the	O
glucocorticoid	B-protein
receptors	I-protein
in	O
various	O
types	O
of	O
leukemic	O
cells	O
and	O
normal	O
lymphocytes	O
and	O
to	O
investigate	O
the	O
role	O
of	O
endogenous	O
peptidases	O
in	O
receptor	O
degradation	O
.	O
Cytosols	O
were	O
prepared	O
from	O
fresh	O
or	O
rapidly	O
frozen	O
leukocytes	O
from	O
6	O
healthy	O
adults	O
and	O
35	O
high-risk	O
leukemia	O
patients	O
(	O
median	O
white	O
blood	O
cell	O
count	O
,	O
150	O
,	O
000	O
cells/microliter	O
;	O
median	O
age	O
,	O
13	O
years	O
)	O
.	O
Receptors	O
were	O
labeled	O
with	O
[	O
3H	O
]	O
triamcinolone	O
acetonide	O
and	O
quantitated	O
by	O
charcoal-dextran	O
treatment	O
or	O
Sephadex	O
LH-20	O
chromatography	O
.	O
Mean	O
and	O
median	B-protein
cytosolic	I-protein
receptor	I-protein
concentrations	O
in	O
12	O
acute	O
lymphoblastic	O
leukemia	O
specimens	O
lacking	O
the	O
standard	O
B-cell	O
or	O
T-cell	O
markers	O
(	O
``	O
null	O
cells	O
''	O
)	O
were	O
approximately	O
4-fold	O
higher	O
than	O
in	O
23	O
other	O
leukemic	O
cell	O
specimens	O
.	O
No	O
other	O
consistent	O
differences	O
in	O
receptor	O
content	O
were	O
observed	O
.	O
Agarose	O
filtration	O
and	O
ultracentrifugation	O
in	O
hypotonic	O
buffers	O
containing	O
20	O
mM	O
Na2MoO4	O
revealed	O
complexes	O
of	O
similar	O
size	O
and	O
shape	O
in	O
all	O
clinical	O
specimens	O
tested	O
and	O
two	O
established	O
leukemic	O
cell	O
lines	O
.	O
They	O
had	O
Stokes	O
radii	O
(	O
Rs	O
)	O
of	O
8.1	O
+/-	O
0.5	O
(	O
)	O
nm	O
(	O
n	O
=	O
50	O
)	O
,	O
sedimentation	O
coefficients	O
of	O
9.5	O
+/-	O
0.3S	O
(	O
n	O
=	O
40	O
)	O
,	O
molecular	O
weights	O
of	O
approximately	O
330	O
,	O
000	O
,	O
and	O
axial	O
ratios	O
(	O
a/b	O
)	O
of	O
approximately	O
12	O
.	O
In	O
hypertonic	O
,	O
molybdate-free	O
buffer	O
,	O
these	O
oligomeric	B-protein
complexes	I-protein
were	O
dissociated	O
into	O
subunits	O
with	O
Rs	O
of	O
5.9	O
+/-	O
0.3	O
nm	O
(	O
n	O
=	O
12	O
)	O
and	O
a/b	O
of	O
11	O
to	O
12	O
,	O
as	O
observed	O
previously	O
for	O
other	O
receptors	O
.	O
Fragmentation	O
of	O
the	O
oligomer	O
and	O
the	O
subunit	B-protein
was	O
evident	O
in	O
some	O
cytosols	O
.	O
High	O
activities	O
of	O
peptidases	O
of	O
various	O
specificities	O
were	O
detected	O
in	O
leukemic	O
cell	O
cytosols	O
,	O
as	O
in	O
other	O
cytosols	O
,	O
by	O
fluorometric	O
assays	O
with	O
derivatives	O
of	O
7-amino-4-methylcoumarin	O
.	O
Receptor	B-protein
cleavage	O
by	O
these	O
and	O
other	O
endogenous	O
enzymes	O
may	O
account	O
for	O
previous	O
observations	O
of	O
``	B-protein
abnormal	I-protein
''	I-protein
receptors	I-protein
in	O
cytosols	O
from	O
some	O
leukemic	O
specimens	O
.	O
We	O
conclude	O
that	O
intrinsic	O
structural	O
defects	O
in	O
the	O
receptors	O
are	O
unlikely	O
explanations	O
for	O
the	O
unresponsiveness	O
of	O
some	O
types	O
of	O
leukemia	O
to	O
steroid	O
therapy	O
.	O
Glucocorticoid	B-protein
receptor	I-protein
number	O
and	O
intracellular	O
water	O
space	O
.	O
In	O
order	O
to	O
elucidate	O
the	O
relationship	O
between	O
cell	O
water	O
content	O
and	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
,	O
eleven	O
normal	O
and	O
malignant	O
lymphoid	O
or	O
myelomonocytic	O
cell	O
types	O
originating	O
from	O
mouse	O
,	O
rat	O
and	O
man	O
were	O
investigated	O
.	O
The	O
cellular	O
water	O
space	O
was	O
measured	O
with	O
3H2O	O
,	O
and	O
glucocorticoid	B-protein
receptor	I-protein
number	O
was	O
measured	O
in	O
a	O
whole-cell	O
binding	O
assay	O
with	O
[	O
3H	O
]	O
dexamethasone	O
at	O
30	O
and	O
37	O
degrees	O
C	O
.	O
The	O
intracellular	O
water	O
phase	O
concentration	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
around	O
40	O
nmol/l	O
cell	O
water	O
)	O
,	O
and	O
the	O
dependence	O
of	O
receptor	O
affinity	O
on	O
temperature	O
were	O
similar	O
in	O
normal	O
and	O
malignant	O
rodent	O
and	O
human	O
cells	O
.	O
It	O
is	O
concluded	O
that	O
comparisons	O
of	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
are	O
best	O
made	O
on	O
the	O
basis	O
of	O
intracellular	B-protein
receptor	I-protein
concentrations	O
.	O
Covalent	O
labeling	O
of	O
rat	O
thymocyte	O
and	O
human	B-protein
lymphoid	I-protein
glucocorticoid	I-protein
receptor	I-protein
.	O
Lymphoid	O
cells	O
contain	O
specific	O
receptors	O
for	O
glucocorticoids	O
.	O
We	O
have	O
used	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	O
to	O
label	O
covalently	O
glucocorticoid	B-protein
receptors	I-protein
in	O
rat	O
thymic	O
lymphocytes	O
and	O
in	O
neoplastic	O
cells	O
obtained	O
from	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
and	O
malignant	O
lymphoma	O
.	O
The	O
covalently	O
labeled	O
glucocorticoid	B-protein
receptors	I-protein
were	O
identified	O
by	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
in	O
the	O
presence	O
of	O
0.1	O
%	O
sodium	O
dodecyl	O
sulfate	O
)	O
.	O
In	O
cytosolic	O
fractions	O
prepared	O
from	O
rat	O
thymic	O
lymphocytes	O
,	O
[	O
3H	O
]	O
-dexamethasone-21-mesylate	O
labels	O
a	O
protein	O
(	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
)	O
which	O
was	O
identified	O
as	O
the	O
glucocorticoid	B-protein
receptor	I-protein
by	O
the	O
following	O
criteria	O
:	O
(	O
a	O
)	O
labeling	O
of	O
this	O
moiety	O
is	O
inhibited	O
by	O
treatment	O
with	O
a	O
100-fold	O
molar	O
excess	O
of	O
glucocorticoids	O
,	O
such	O
as	O
dexamethasone	O
and	O
triamcinolone	O
acetonide	O
;	O
and	O
(	O
b	O
)	O
the	O
covalently	O
labeled	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
protein	O
is	O
activated	O
(	O
by	O
heating	O
at	O
20	O
degrees	O
for	O
30	O
min	O
)	O
to	O
a	O
form	O
that	O
binds	O
to	O
DNA-cellulose	O
.	O
When	O
intact	O
thymocytes	O
are	O
treated	O
with	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	O
,	O
an	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
moiety	O
is	O
also	O
labeled	O
covalently	O
.	O
Approximately	O
35	O
%	O
of	O
the	O
glucocorticoid	B-protein
receptors	I-protein
can	O
be	O
labeled	O
covalently	O
when	O
intact	O
thymocytes	O
are	O
treated	O
with	O
100	O
nM	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	O
for	O
30	O
min	O
at	O
4	O
degrees	O
.	O
Neoplastic	O
cells	O
from	O
acute	O
lymphoblastic	O
leukemia	O
and	O
malignant	O
lymphoma	O
were	O
treated	O
with	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	O
.	O
In	O
all	O
samples	O
,	O
an	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
moiety	O
was	O
labeled	O
covalently	O
;	O
labeling	O
was	O
inhibited	O
by	O
excess	O
glucocorticoid	O
.	O
Smaller	O
moieties	O
were	O
also	O
identified	O
by	O
competition	O
experiments	O
;	O
these	O
may	O
represent	O
proteolytic	O
fragments	O
of	O
the	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
receptor	O
.	O
Thus	O
,	O
in	O
rat	O
and	O
human	O
lymphoid	O
cells	O
,	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	O
can	O
be	O
used	O
to	O
label	O
covalently	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O
The	O
association	O
of	O
cytosol	O
oestrogen	B-protein
and	I-protein
progesterone	I-protein
receptors	I-protein
with	O
histological	O
features	O
of	O
breast	O
cancer	O
and	O
early	O
recurrence	O
of	O
disease	O
.	O
Two	O
hundred	O
and	O
eighty-eight	O
primary	O
breast	O
tumours	O
were	O
examined	O
for	O
the	O
presence	O
or	O
absence	O
of	O
oestrogen	O
(	O
REc	O
)	O
and	O
progesterone	O
(	O
RPc	B-protein
)	I-protein
receptors	I-protein
.	O
Analysis	O
has	O
shown	O
a	O
relative	O
interdependence	O
between	O
the	O
steroid	O
receptor	O
status	O
of	O
primary	O
breast	O
cancer	O
and	O
other	O
prognostic	O
variables	O
such	O
as	O
histological	O
grade	O
,	O
lymphocytic	O
infiltration	O
and	O
tumour	O
elastosis	O
.	O
There	O
were	O
significant	O
associations	O
between	O
epithelial	O
cellularity	O
,	O
stromal	O
fibrosis	O
and	O
the	O
value	O
of	O
REc	O
in	O
those	O
tumours	O
in	O
which	O
the	O
receptor	O
was	O
present	O
.	O
Cellularity	O
and	O
fibrosis	O
were	O
unrelated	O
to	O
the	O
presence	O
or	O
absence	O
of	O
oestrogen	B-protein
receptor	I-protein
.	O
By	O
contrast	O
,	O
neither	O
the	O
presence	O
or	O
absence	O
nor	O
the	O
value	O
of	O
RPc	O
could	O
be	O
related	O
to	O
cellularity	O
or	O
fibrosis	O
.	O
The	O
value	O
of	O
REc	O
and	O
RPc	O
analysis	O
as	O
an	O
indicator	O
of	O
prognosis	O
was	O
examined	O
in	O
a	O
sub-group	O
of	O
175	O
patients	O
receiving	O
no	O
additional	O
treatment	O
following	O
mastectomy	O
.	O
Overall	O
relapse-free	O
survival	O
(	O
RFS	O
)	O
was	O
no	O
different	O
for	O
those	O
patients	O
with	O
receptors	O
compared	O
to	O
those	O
without	O
them	O
(	O
REc	O
P	O
=	O
0.11	O
,	O
RPc	O
P	O
=	O
0.7	O
)	O
.	O
There	O
was	O
no	O
difference	O
in	O
RFS	O
of	O
receptor	O
positive	O
and	O
negative	O
tumours	O
when	O
the	O
axillary	O
node	O
status	O
was	O
taken	O
into	O
account	O
.	O
Clinical	O
implications	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	O
leukemia	O
.	O
Normal	O
lymphoid	O
cells	O
contain	O
glucocorticoid	B-protein
receptor	I-protein
.	O
A	O
variety	O
of	O
stimuli	O
that	O
activate	O
these	O
cells	O
also	O
induce	O
increases	O
in	O
receptor	O
concentration	O
.	O
Similar	O
glucocorticoid	B-protein
receptors	I-protein
can	O
be	O
detected	O
in	O
lymphoid	O
cells	O
from	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
.	O
Absence	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
(	O
usually	O
found	O
in	O
treated	O
patients	O
)	O
predicts	O
lack	O
of	O
glucocorticoid	O
responsiveness	O
.	O
Furthermore	O
,	O
in	O
our	O
hands	O
,	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
correlate	O
with	O
the	O
duration	O
of	O
complete	O
remission	O
in	O
ALL	O
(	O
though	O
not	O
in	O
other	O
forms	O
of	O
leukemia	O
)	O
.	O
This	O
association	O
is	O
independent	O
of	O
cell	O
type	O
,	O
age	O
,	O
sex	O
,	O
or	O
initial	O
leukocyte	O
count	O
.	O
The	O
level	O
of	O
receptor	O
shows	O
a	O
negative	O
correlation	O
with	O
increasing	O
aggressiveness	O
of	O
the	O
tumor	O
(	O
null-cell	O
leukemia	O
greater	O
than	O
T-cell	O
leukemia	O
greater	O
than	O
Burkitt	O
's	O
lymphoma	O
)	O
.	O
Corticosteroid-mediated	O
immunoregulation	O
in	O
man	O
.	O
Glucocorticoids	O
have	O
profound	O
and	O
complex	O
effects	O
on	O
the	O
human	O
immune	O
response	O
.	O
However	O
,	O
the	O
precise	O
mechanisms	O
of	O
the	O
corticosteroid-induced	O
immunoregulation	O
in	O
man	O
have	O
not	O
been	O
precisely	O
defined	O
.	O
Intracytoplasmic	B-protein
corticosteroid-specific	I-protein
receptors	I-protein
appear	O
to	O
be	O
an	O
important	O
common	O
pathway	O
for	O
steroid-induced	O
changes	O
,	O
but	O
variations	O
of	O
receptor	O
parameters	O
do	O
not	O
account	O
for	O
the	O
multifaceted	O
effects	O
on	O
the	O
immune	O
system	O
.	O
Human	O
circulating	O
mononuclear	O
cells	O
redistribute	O
out	O
of	O
the	O
intravascular	O
compartment	O
following	O
treatment	O
with	O
corticosteroids	O
.	O
Although	O
certain	O
components	O
at	O
this	O
redistribution	O
phenomenon	O
have	O
been	O
well-characterized	O
,	O
the	O
importance	O
of	O
this	O
compartmental	O
cellular	O
shift	O
with	O
respect	O
to	O
the	O
mechanisms	O
of	O
corticosteroid-induced	O
immunoregulation	O
are	O
less	O
well-defined	O
.	O
Recent	O
observations	O
that	O
activated	O
lymphocytes	O
may	O
be	O
sensitive	O
to	O
the	O
lytic	O
effects	O
of	O
glucocorticoids	O
suggest	O
that	O
under	O
certain	O
situations	O
the	O
elimination	O
of	O
selected	O
subsets	O
of	O
cells	O
may	O
be	O
a	O
relevant	O
mechanism	O
of	O
corticosteroid-mediated	O
immunoregulation	O
in	O
man	O
.	O
Corticosteroid-mediated	O
effects	O
on	O
monocyte	O
function	O
may	O
be	O
an	O
important	O
mechanism	O
of	O
drug-induced	O
immunoregulation	O
in	O
monocyte-dependent	O
responses	O
.	O
In	O
some	O
experimental	O
conditions	O
,	O
corticosteroids	O
inhibit	O
Interleukin	B-protein
1	I-protein
production	O
by	O
monocytes	O
.	O
The	O
immunoregulatory	O
effects	O
of	O
corticosteroids	O
on	O
lymphocyte	O
immune	O
responses	O
are	O
complex	O
.	O
In	O
vitro	O
corticosteroids	O
appear	O
to	O
selectively	O
affect	O
early	O
immunoregulatory	O
events	O
as	O
opposed	O
to	O
altering	O
an	O
established	O
response	O
.	O
Multiple	O
sites	O
of	O
steroid-induced	O
modulations	O
of	O
human	O
B	O
cell	O
responses	O
have	O
been	O
defined	O
.	O
Human	O
lymphoid	O
cell	O
lines	O
and	O
glucocorticoids	O
:	O
II	O
.	O
Whole	B-protein
cell	I-protein
and	I-protein
cytoplasmic	I-protein
binding	I-protein
properties	I-protein
of	O
lymphoblastoid	O
,	O
leukaemia	O
and	O
lymphoma	O
lines	O
.	O
The	O
glucocorticoid	O
binding	O
properties	O
of	O
18	O
human	O
lymphoid	O
cell	O
lines	O
(	O
HLCL	O
)	O
have	O
been	O
investigated	O
.	O
The	O
specificity	O
of	O
steroid	O
binding	O
was	O
confirmed	O
with	O
various	O
glucocorticoid	O
agonists	O
and	O
antagonists	O
.	O
A	O
gradation	O
in	O
whole	O
cell	O
and	O
cytoplasmic	B-protein
glucocorticoid	I-protein
binding	I-protein
capacity	I-protein
was	O
observed	O
in	O
the	O
different	O
cell	O
line	O
types	O
:	O
lymphoblastoid	O
greater	O
than	O
lymphoma	O
greater	O
than	O
leukaemia	O
.	O
The	O
cytoplasmic	B-protein
receptors	I-protein
of	O
leukaemia	O
and	O
lymphoblastoid	O
lines	O
appeared	O
to	O
contain	O
both	O
proteinaceous	O
and	O
phospholipid	O
components	O
.	O
Cytoplasmic	B-protein
steroid-receptor	I-protein
complexes	I-protein
exhibited	O
a	O
wide	O
range	O
of	O
sedimentation	O
coefficients	O
(	O
8.5-11.3S	O
)	O
in	O
low	O
ionic	O
strength	O
buffer	O
but	O
there	O
was	O
no	O
correlation	O
with	O
cell	O
line	O
type	O
or	O
glucocorticoid	O
sensitivity	O
.	O
Activation	O
of	O
these	O
complexes	O
by	O
heat	O
(	O
37	O
degrees	O
C	O
)	O
or	O
exposure	O
to	O
high	O
ionic	O
strength	O
buffer	O
(	O
0.3	O
M	O
NaCl	O
)	O
induced	O
nuclear	O
binding	O
of	O
steroid	O
but	O
only	O
complexes	O
in	O
high	O
ionic	O
strength	O
buffer	O
manifested	O
changes	O
in	O
sedimentation	O
coefficient	O
.	O
No	O
correlation	O
was	O
observed	O
between	O
the	O
level	O
or	O
nature	O
of	O
glucocorticoid	O
binding	O
and	O
the	O
cytolethal	O
or	O
cytostatic	O
responsiveness	O
of	O
HLCL	O
to	O
glucocorticoid	O
treatment	O
in	O
vitro	O
.	O
The	O
resistance	O
to	O
cytolethal	O
effects	O
can	O
not	O
be	O
ascribed	O
to	O
a	O
failure	O
of	O
cells	O
to	O
take	O
up	O
and	O
bind	O
steroid	O
or	O
to	O
significant	O
differences	O
in	O
the	O
molecular	O
species	O
of	O
cytoplasmic	B-protein
receptors	I-protein
present	O
.	O
The	O
molecular	O
mechanisms	O
by	O
which	O
glucocorticoids	O
achieve	O
cytolethal	O
responses	O
in	O
human	O
lymphoid	O
cells	O
CD28	B-protein
-mediated	O
activation	O
in	O
CD45RA+	O
and	O
CD45RO+	O
T	O
cells	O
:	O
enhanced	O
levels	O
of	O
reactive	O
oxygen	O
intermediates	O
and	O
c-Rel	O
nuclear	O
translocation	O
in	O
CD45RA+	O
cells	O
.	O
We	O
have	O
analyzed	O
the	O
effect	O
of	O
complete	O
T	O
cell	O
activation	O
(	O
anti-CD3	O
plus	O
anti-CD28	O
)	O
on	O
the	O
activation	O
of	O
NF-kappaB	B-protein
in	O
CD45RA+	O
(	O
naive	O
)	O
and	O
CD45RO+	O
(	O
memory/effector	O
)	O
T	O
cells	O
.	O
Long	O
exposure	O
(	O
24	O
h	O
)	O
induced	O
stronger	O
NF-kappaB	B-protein
DNA	O
binding	O
in	O
CD45RA+	O
cells	O
than	O
in	O
CD45RO+	O
cells	O
.	O
Analysis	O
of	O
the	O
nuclear	B-protein
c-Rel	I-protein
protein	I-protein
indicated	O
that	O
after	O
anti-CD3+anti-CD28	O
stimulation	O
the	O
level	O
of	O
c-Rel	B-protein
was	O
higher	O
in	O
CD45RA+	O
cells	O
.	O
Analysis	O
of	O
the	O
cytoplasmic	B-protein
inhibitor	I-protein
IkappaBalpha	B-protein
indicated	O
that	O
anti-CD3+anti-CD28	O
stimulation	O
induced	O
a	O
long-lasting	O
degradation	O
in	O
CD45RA+	O
cells	O
but	O
in	O
CD45RO+	O
cells	O
the	O
degradation	O
process	O
was	O
more	O
rapid	O
.	O
Because	O
the	O
CD28	B-protein
costimulus	O
is	O
known	O
to	O
induce	O
the	O
production	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
,	O
the	O
intracellular	O
ROI	O
levels	O
in	O
CD45RA+	O
and	O
CD45RO+	O
cells	O
were	O
compared	O
by	O
flow	O
cytometry	O
.	O
ROIs	O
were	O
produced	O
in	O
both	O
cell	O
types	O
,	O
but	O
more	O
strongly	O
in	O
CD45RA+	O
cells	O
.	O
The	O
data	O
presented	O
in	O
this	O
study	O
further	O
emphasize	O
the	O
differences	O
between	O
CD45RA+	O
and	O
CD45RO+	O
T	O
lymphocytes	O
in	O
ROI-dependent	O
signaling	O
pathways	O
.	O
Ikaros	B-protein
in	O
hemopoietic	O
lineage	O
determination	O
and	O
homeostasis	O
.	O
Studies	O
on	O
the	O
molecular	O
mechanisms	O
that	O
control	O
hemopoietic	O
differentiation	O
have	O
focused	O
on	O
signaling	O
cascades	O
and	O
nuclear	O
effectors	O
that	O
drive	O
this	O
complex	O
developmental	O
system	O
in	O
a	O
regulated	O
fashion	O
.	O
Here	O
we	O
review	O
the	O
role	O
of	O
Ikaros	B-protein
,	O
the	O
founding	O
member	O
of	O
a	O
unique	O
family	O
of	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factors	I-protein
in	O
this	O
developmental	O
process	O
.	O
Studies	O
on	O
an	O
Ikaros	B-protein
null	O
mutation	O
have	O
revealed	O
an	O
essential	O
role	O
for	O
this	O
factor	O
in	O
lymphoid	O
cell	O
fate	O
determination	O
and	O
at	O
subsequent	O
branch	O
points	O
of	O
the	O
T	O
cell	O
differentiation	O
pathway	O
.	O
Differences	O
in	O
the	O
phenotypes	O
of	O
a	O
null	O
and	O
a	O
dominant	O
negative	O
(	O
DN	O
)	O
Ikaros	O
mutation	O
provide	O
insight	O
into	O
a	O
regulatory	O
network	O
through	O
which	O
Ikaros	B-protein
proteins	I-protein
exert	O
their	O
effects	O
in	O
development	O
.	O
In	O
addition	O
a	O
comparative	O
analysis	O
of	O
the	O
hemopoietic	O
stem	O
cell	O
and	O
precursor	O
compartment	O
resulting	O
from	O
the	O
two	O
Ikaros	O
mutations	O
reveals	O
a	O
profound	O
yet	O
not	O
absolute	O
requirement	O
for	O
Ikaros	B-protein
in	O
the	O
production	O
and	O
differentiation	O
of	O
these	O
populations	O
.	O
Overexpression	O
of	O
p65	B-protein
and	O
c-Jun	O
substitutes	O
for	O
B7-1	O
costimulation	O
by	O
targeting	O
the	O
CD28RE	B-protein
within	O
the	O
IL-2	O
promoter	O
.	O
The	O
role	O
of	O
Rel	O
and	O
activation	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
in	O
IL-2	O
promoter	O
activity	O
in	O
B7-1-	O
and	O
leukocyte	O
function-associated	O
Ag-3	O
(	O
3	O
)	O
-costimulated	O
T	O
cells	O
has	O
been	O
evaluated	O
.	O
We	O
demonstrate	O
that	O
overexpression	O
of	O
c-Jun	B-protein
but	O
not	O
c-Fos	O
increases	O
IL-2	O
promoter	O
activity	O
in	O
both	O
B7-1-	O
and	O
LFA-3-costimulated	O
Jurkat	O
T	O
cells	O
.	O
Cotransfection	O
of	O
both	O
c-Jun	B-protein
and	O
c-Fos	O
substitutes	O
for	O
B7-1	O
costimulation	O
in	O
driving	O
an	O
activation	O
protein-1	O
response	O
element	O
but	O
not	O
for	O
the	O
IL-2	O
promoter	O
.	O
Overexpression	O
of	O
Rel	B-protein
proteins	I-protein
demonstrated	O
that	O
p65-expressing	O
Jurkat	O
cells	O
transcribed	O
equally	O
well	O
a	O
nuclear	O
factor	O
kappabeta	O
reporter	O
construct	O
when	O
costimulated	O
with	O
B7-1	O
or	O
LFA-3	O
,	O
but	O
transcription	O
of	O
IL-2	O
promoter	O
or	O
CD28	O
response	O
element	O
(	O
CD28RE	O
)	O
-driven	O
reporters	O
was	O
superior	O
in	O
B7-1-costimulated	O
cells	O
.	O
Combined	O
expression	O
of	O
c-Jun	B-protein
and	O
p65	B-protein
induced	O
vigorous	O
transcription	O
of	O
IL-2	B-protein
promoter-	O
and	O
CD28RE-driven	O
reporter	O
constructs	O
in	O
both	O
LFA-3-	O
and	O
B7-1-costimulated	O
Jurkat	O
cells	O
.	O
Mutating	O
the	O
CD28RE	B-protein
but	O
not	O
the	O
upstream	O
nuclear	O
factor	O
kappabeta-binding	O
site	O
in	O
the	O
IL-2	O
promoter	O
reduced	O
B7-1	B-protein
-driven	I-protein
transcription	I-protein
>	I-protein
90	I-protein
%	I-protein
.	O
The	O
results	O
implicates	O
a	O
major	O
role	O
of	O
the	O
CD28RE	B-protein
in	O
the	O
integration	O
of	O
p65	B-protein
/	O
c-Jun	B-protein
-mediated	O
transcription	O
within	O
the	O
IL-2	O
promoter	O
.	O
We	O
suggest	O
that	O
the	O
transition	O
from	O
an	O
autocrine	O
LFA-3	O
-driven	O
immune	O
response	O
to	O
a	O
B7	O
--	O
induced	O
paracrine	O
immune	O
response	O
involves	O
the	O
activation	O
of	O
c-Jun	B-protein
and	O
p65	B-protein
,	O
which	O
target	O
the	O
CD28RE	O
region	O
of	O
the	O
IL-2	O
promoter	O
.	O
Defects	O
in	O
actin-cap	O
formation	O
in	O
Vav-deficient	O
mice	O
implicate	O
an	O
actin	O
requirement	O
for	O
lymphocyte	O
signal	O
transduction	O
.	O
BACKGROUND	O
:	O
Antigen-receptor	O
interactions	O
on	O
lymphocytes	O
result	O
in	O
local	O
clustering	O
of	O
actin	O
,	O
receptors	O
and	O
signaling	B-protein
molecules	I-protein
into	O
an	O
asymmetric	O
membrane	O
structure	O
termed	O
a	O
cap	O
.	O
Although	O
actin	O
polymerization	O
is	O
known	O
to	O
be	O
required	O
,	O
the	O
mechanisms	O
underlying	O
cap	O
formation	O
are	O
unclear	O
.	O
We	O
have	O
studied	O
the	O
events	O
underlying	O
cap	O
formation	O
using	O
mice	O
bearing	O
a	O
null	O
mutation	O
in	O
vav	O
(	O
vav	O
-/-	O
)	O
,	O
a	O
gene	O
that	O
encodes	O
a	O
guanine-nucleotide	O
exchange	O
factor	O
for	O
the	O
GTPase	O
Rac	O
.	O
RESULTS	O
:	O
Lymphocytes	O
from	O
vav	O
-/-	O
mice	O
failed	O
to	O
form	O
T-cell	B-protein
receptor	I-protein
caps	O
following	O
activation	O
and	O
had	O
a	O
defective	O
actin	O
cytoskeleton	O
.	O
The	O
vav-/-	O
T	O
cells	O
were	O
deficient	O
in	O
interleukin-2	O
(	O
IL-2	B-protein
)	O
production	O
and	O
proliferation	O
,	O
and	O
the	O
peak	O
of	O
Ca2+	O
mobilization	O
was	O
reduced	O
although	O
of	O
normal	O
duration	O
.	O
Activation	O
of	O
Jun	B-protein
N-terminal	I-protein
kinase	I-protein
or	O
stress-activated	B-protein
kinase	I-protein
(	O
JNK	B-protein
or	O
SAPK	O
)	O
and	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
and	O
the	O
induction	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-ATc1	I-protein
and	O
egr-1	O
genes	O
was	O
normal	O
.	O
Despite	O
the	O
reduced	O
Ca2+	O
mobilization	O
,	O
translocation	O
of	O
cytoplasmic	B-protein
NF-ATc	I-protein
to	O
the	O
nucleus	O
was	O
normal	O
,	O
reflecting	O
that	O
the	O
lower	O
levels	O
of	O
Ca2+	O
in	O
vav-/-	O
cells	O
were	O
still	O
sufficient	O
to	O
activate	O
calcineurin	B-protein
.	O
Treatment	O
of	O
lymphocytes	O
with	O
cytochalasin	O
D	O
,	O
which	O
blocks	O
actin	O
polymerization	O
,	O
inhibited	O
cap	O
formation	O
and	O
produced	O
defects	O
in	O
signaling	O
and	O
IL-2	B-protein
transcriptional	O
induction	O
in	O
response	O
to	O
antigen-receptor	O
signaling	O
that	O
were	O
nearly	O
identical	O
to	O
those	O
seen	O
in	O
vav-/-	O
cells	O
.	O
In	O
transfection	O
studies	O
,	O
either	O
constitutively	O
active	O
Vav	O
or	O
Rac	O
could	O
complement	O
constitutively	O
active	O
calcineurin	B-protein
to	O
activate	O
NF-AT-dependent	O
transcription	O
.	O
CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
Vav	O
is	O
required	O
for	O
cap	O
formation	O
in	O
lymphocytes	O
.	O
Furthermore	O
,	O
the	O
correlation	O
between	O
cap	O
formation	O
,	O
IL-2	B-protein
production	O
and	O
proliferation	O
supports	O
the	O
hypothesis	O
that	O
an	O
actin-dependent	O
pathway	O
is	O
a	O
source	O
of	O
specialized	O
growth	O
regulatory	O
signals	O
.	O
CD14	B-protein
-dependent	O
activation	O
of	O
human	O
endothelial	O
cells	O
by	O
Bacteroides	O
fragilis	O
outer	O
membrane	O
.	O
We	O
studied	O
the	O
capacity	O
of	O
isolated	O
Bacteriodes	O
fragilis	O
outer	O
membrane	O
,	O
B.	O
fragilis	O
NCTC9343	O
lipopolysaccharide	O
(	O
LPS	O
;	O
endotoxin	O
)	O
,	O
and	O
B.	O
fragilis	O
NCTC9343	O
capsular	O
polysaccharides	O
to	O
activate	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
(	O
HUVEC	O
)	O
monolayers	O
.	O
To	O
assess	O
HUVEC	O
activation	O
,	O
E-selectin	O
expression	O
was	O
measured	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
,	O
Northern	O
blot	O
analysis	O
for	O
E-selectin-specific	O
mRNA	O
,	O
and	O
electrophoretic	O
gel	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
for	O
NF-kappa	B-protein
B	I-protein
,	O
a	O
transcription	O
factor	O
necessary	O
for	O
E-selectin	O
gene	O
activation	O
.	O
Exposure	O
of	O
HUVECs	O
to	O
B.	O
fragilis	O
outer	O
membrane	O
fractions	O
,	O
separated	O
from	O
other	O
components	O
of	O
the	O
B.	O
fragilis	O
cell	O
wall	O
by	O
isopycnic	O
,	O
sucrose	O
gradient	O
centrifugation	O
,	O
significantly	O
increased	O
surface	O
expression	O
of	O
E-selectin	B-protein
and	O
induced	O
functional	O
endothelial	O
cell	O
-dependent	O
leukocyte	O
adhesion	O
.	O
B.	O
fragilis	O
outer	O
membranes	O
induced	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
to	O
HUVEC	O
nuclei	O
and	O
accumulation	O
of	O
E-selectin	O
mRNA	O
in	O
HUVEC	O
cytoplasm	O
.	O
E-selectin	O
expression	O
induced	O
by	O
B.	O
fragilis	O
outer	O
membranes	O
was	O
not	O
blocked	O
by	O
polymixin	O
B	O
.	O
In	O
contrast	O
,	O
E-selectin	O
expression	O
induced	O
by	O
outer	O
membrane	O
fractions	O
purified	O
from	O
E.	O
coli	O
was	O
competitively	O
inhibited	O
by	O
polymixin	O
B	O
.	O
Neither	O
purified	O
B.	O
fragilis	O
LPS	O
,	O
a	O
prominent	O
constituent	O
of	O
the	O
outer	O
membrane	O
,	O
nor	O
purified	O
B.	O
fragilis	O
capsular	O
polysaccharides	O
induced	O
HUVEC	O
activation	O
.	O
Two	O
different	O
monoclonal	B-protein
antibodies	I-protein
directed	O
against	O
human	O
CD14	O
completely	O
inhibited	O
B.	O
fragilis	O
outer	O
membrane-induced	O
NF-kappa	O
B	O
activation	O
,	O
E-selectin	O
transcription	O
,	O
and	O
E-selectin	O
surface	O
expression	O
.	O
We	O
conclude	O
that	O
the	O
outer	O
membrane	O
component	O
of	O
the	O
B.	O
fragilis	O
cell	O
wall	O
contains	O
a	O
proinflammatory	B-protein
factor	I-protein
(	O
s	O
)	O
,	O
that	O
is	O
not	O
LPS	O
,	O
which	O
induces	O
human	O
endothelial	O
cell	O
activation	O
by	O
a	O
soluble	O
CD14	B-protein
-dependent	O
mechanism	O
.	O
NF-kappaB	O
protects	O
HIV-1-infected	O
myeloid	O
cells	O
from	O
apoptosis	O
.	O
HIV-1	O
infection	O
of	O
primary	O
monocytic	O
cells	O
and	O
myeloid	O
cell	O
lines	O
results	O
in	O
sustained	O
NF-kappaB	O
activation	O
.	O
Recently	O
,	O
NF-kappaB	B-protein
induction	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
protecting	O
cells	O
from	O
programmed	O
cell	O
death	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
sought	O
to	O
investigate	O
whether	O
constitutive	O
NF-kappaB	O
activity	O
in	O
chronically	O
HIV-1-infected	O
promonocytic	O
U937	O
(	O
U9-IIIB	O
)	O
and	O
myeloblastic	O
PLB-985	O
(	O
PLB-IIIB	O
)	O
cells	O
affects	O
apoptotic	O
signaling	O
.	O
TNFalpha	B-protein
and	O
cycloheximide	O
caused	O
infected	O
cells	O
to	O
undergo	O
apoptosis	O
more	O
rapidly	O
than	O
parental	O
U937	O
and	O
PLB-985	O
cells	O
.	O
Inhibition	O
of	O
TNFalpha	B-protein
-induced	O
NF-kappaB	B-protein
activation	O
using	O
the	O
antioxidant	O
N-acetylcysteine	O
(	O
NAC	O
)	O
resulted	O
in	O
increased	O
apoptosis	O
in	O
both	O
U937	O
and	O
U9-IIIB	O
cells	O
,	O
while	O
preactivation	O
of	O
NF-kappaB	B-protein
with	O
the	O
non-apoptotic	O
inducer	O
IL-1beta	O
caused	O
a	O
relative	O
decrease	O
in	O
apoptosis	O
.	O
Inhibition	O
of	O
constitutive	O
NF-kappaB	O
activity	O
in	O
U9-IIIB	O
and	O
PLB-IIIB	O
cells	O
also	O
induced	O
apoptosis	O
,	O
suggesting	O
that	O
NF-kappaB	B-protein
protects	O
cells	O
from	O
a	O
persistent	O
apoptotic	O
signal	O
.	O
TNFalpha	B-protein
plus	O
NAC	O
treatment	O
resulted	O
in	O
a	O
marked	O
decrease	O
in	O
Bcl-2	O
protein	O
levels	O
in	O
HIV-1-infected	O
cells	O
,	O
coupled	O
with	O
an	O
increase	O
in	O
Bax	O
protein	O
compared	O
to	O
uninfected	O
cells	O
,	O
suggesting	O
that	O
the	O
difference	O
in	O
susceptibility	O
to	O
TNFalpha	B-protein
-induced	O
apoptosis	O
may	O
relate	O
to	O
the	O
differences	O
in	O
relative	O
levels	O
of	O
Bcl-2	B-protein
and	O
Bax	O
.	O
The	O
protective	O
role	O
of	O
NF-kappaB	B-protein
in	O
blocking	O
TNFalpha-	B-protein
and	O
HIV-1-induced	O
apoptosis	O
was	O
supported	O
by	O
studies	O
in	O
Jurkat	O
T	O
cells	O
engineered	O
to	O
express	O
IkappaB	O
alpha	O
repressor	O
mutants	O
(	O
TD-IkappaB	O
)	O
under	O
the	O
control	O
of	O
a	O
tetracycline-responsive	O
promoter	O
.	O
Cells	O
underwent	O
apoptosis	O
in	O
response	O
to	O
TNFalpha	B-protein
only	O
when	O
NF-kappaB	O
activation	O
was	O
inhibited	O
by	O
TD-IkappaB	O
expression	O
.	O
As	O
was	O
observed	O
for	O
the	O
U9-IIIB	O
cells	O
,	O
TNFalpha	B-protein
treatment	O
also	O
induced	O
a	O
marked	O
decrease	O
in	O
Bcl-2	O
protein	O
levels	O
in	O
TD-IkappaB	O
expressing	O
cells	O
.	O
These	O
experiments	O
demonstrate	O
that	O
apoptotic	O
signaling	O
is	O
perturbed	O
in	O
HIV-1-infected	O
U9-IIIB	O
cells	O
and	O
indicate	O
that	O
NF-kappaB	B-protein
activation	O
may	O
play	O
an	O
additional	O
protective	O
role	O
against	O
HIV-1-induced	O
apoptosis	O
in	O
myeloid	O
cells	O
.	O
Human	O
normal	O
peripheral	O
blood	O
B-lymphocytes	O
are	O
deficient	O
in	O
DNA-dependent	B-protein
protein	I-protein
kinase	I-protein
activity	O
due	O
to	O
the	O
expression	O
of	O
a	O
variant	O
form	O
of	O
the	O
Ku86	B-protein
protein	I-protein
.	O
The	O
heterodimeric	B-protein
Ku	I-protein
protein	I-protein
,	O
which	O
comprises	O
a	O
86	O
kDa	O
(	O
Ku86	O
)	O
amd	O
a	O
70	B-protein
kDa	I-protein
(	I-protein
Ku70	I-protein
)	I-protein
subunits	I-protein
,	O
is	O
an	O
abundant	O
nuclear	O
DNA-binding	O
protein	O
which	O
binds	O
in	O
vitro	O
to	O
DNA	O
termini	O
without	O
sequence	O
specificity	O
.	O
Ku	O
is	O
the	O
DNA-targeting	O
component	O
of	O
the	O
large	O
catalytic	O
sub-unit	O
of	O
the	O
DNA-dependent	B-protein
protein	I-protein
kinase	I-protein
complex	I-protein
(	O
DNA-PK	O
[	O
CS	O
]	O
)	O
,	O
that	O
plays	O
a	O
critical	O
role	O
in	O
mammalian	O
double-strand	O
break	O
repair	O
and	O
lymphoid	O
V	O
(	O
D	O
)	O
J	O
recombination	O
.	O
By	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
demonstrated	O
that	O
in	O
addition	O
to	O
the	O
major	O
Ku	O
x	O
DNA	O
complex	O
usually	O
detected	O
in	O
cell	O
line	O
extracts	O
,	O
a	O
second	O
complex	O
with	O
faster	O
electrophoretic	O
mobility	O
was	O
observed	O
in	O
normal	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
extracts	O
.	O
The	O
presence	O
of	O
this	O
faster	O
migrating	O
complex	O
was	O
restricted	O
to	O
B	O
cells	O
among	O
the	O
circulating	O
lymphocyte	O
population	O
.	O
Western	O
blot	O
analysis	O
revealed	O
that	O
B	O
cells	O
express	O
a	O
variant	O
form	O
of	O
the	O
Ku86	B-protein
protein	I-protein
with	O
an	O
apparent	O
molecular	O
weight	O
of	O
69	O
kDa	O
,	O
and	O
not	O
the	O
86	O
kDa-	O
full-length	B-protein
protein	I-protein
.	O
Although	O
the	O
heterodimer	O
Ku70/variant-Ku86	O
binds	O
to	O
DNA-ends	O
,	O
this	O
altered	O
form	O
of	O
the	O
Ku	B-protein
heterodimer	I-protein
has	O
a	O
decreased	O
ability	O
to	O
recruit	O
the	O
catalytic	O
component	O
of	O
the	O
complex	O
,	O
DNA-PK	O
(	O
CS	O
)	O
,	O
which	O
contributes	O
to	O
an	O
absence	O
of	O
detectable	O
DNA-PK	O
activity	O
in	O
B	O
cells	O
.	O
These	O
data	O
provide	O
a	O
molecular	O
basis	O
for	O
the	O
increased	O
sensitivity	O
of	O
B	O
cells	O
to	O
ionizing	O
radiation	O
and	O
identify	O
a	O
new	O
mechanism	O
of	O
regulation	O
of	O
DNA-PK	O
activity	O
that	O
operates	O
in	O
vivo	O
.	O
Co-stimulation	O
of	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
with	O
IL-2	B-protein
and	O
anti-CD3	B-protein
monoclonal	I-protein
antibodies	I-protein
induces	O
phosphorylation	O
of	O
CREB	B-protein
.	O
Phosphorylation	O
of	O
the	O
cAMP-response	B-protein
element	I-protein
binding	I-protein
protein	I-protein
CREB	I-protein
within	O
1	O
h	O
of	O
CD2	B-protein
but	O
not	O
CD3	O
cross-linking	O
of	O
human	O
PBMC	O
was	O
recently	O
demonstrated	O
.	O
The	O
absence	O
of	O
P-CREB	O
following	O
CD3	O
cross-linking	O
was	O
unexpected	O
,	O
as	O
other	O
laboratories	O
reported	O
increased	O
phosphorylation	O
of	O
CREB	B-protein
following	O
CD3	O
cross-linking	O
of	O
the	O
Jurkat	O
lymphocyte	O
cell	O
line	O
.	O
Due	O
to	O
Jurkat	O
T-cells	O
being	O
IL-2-independent	O
,	O
it	O
was	O
postulated	O
that	O
IL-2	B-protein
might	O
provide	O
a	O
necessary	O
co-stimulus	O
for	O
phosphorylation	O
of	O
CREB	B-protein
in	O
primary	O
lymphocytes	O
.	O
Therefore	O
,	O
P-CREB	O
was	O
evaluated	O
following	O
co-stimulation	O
of	O
human	O
PBMC	O
through	O
the	O
IL-2	B-protein
and	O
CD2	B-protein
or	O
CD3	B-protein
receptors	I-protein
.	O
IL-2	B-protein
did	O
not	O
further	O
augment	O
phosphorylation	O
of	O
CREB	B-protein
following	O
CD2	O
cross-linking	O
.	O
However	O
,	O
while	O
neither	O
IL-2	B-protein
nor	O
CD3	B-protein
cross-linking	O
alone	O
induced	O
P-CREB	O
,	O
a	O
4.5-fold	O
increase	O
in	O
phosphorylation	O
of	O
CREB	B-protein
within	O
1	O
h	O
of	O
IL-2/CD3	O
co-stimulation	O
was	O
observed	O
.	O
Phosphorylation	O
was	O
not	O
associated	O
with	O
the	O
induction	O
of	O
cAMP	O
,	O
and	O
inhibition	O
of	O
PKA	O
signaling	O
had	O
no	O
effect	O
on	O
P-CREB	O
.	O
Consistent	O
with	O
signal	O
transduction	O
through	O
p56lck	O
or	O
p59fyn	O
,	O
inhibition	O
of	O
PTK	B-protein
signaling	O
reduced	O
phosphorylation	O
50	O
%	O
.	O
Interestingly	O
,	O
inhibiting	O
PKC	B-protein
signaling	O
with	O
calphostin	O
C	O
further	O
increased	O
P-CREB	O
levels	O
3-fold	O
over	O
that	O
observed	O
in	O
IL-2/CD3	O
co-stimulated	O
cells	O
not	O
pretreated	O
with	O
a	O
PKC	O
inhibitor	O
.	O
In	O
contrast	O
to	O
previous	O
studies	O
performed	O
in	O
the	O
absence	O
of	O
exogenous	B-protein
IL-2	I-protein
,	O
no	O
increase	O
in	O
binding	O
of	O
CREB	B-protein
to	O
a	O
32P-labeled	O
oligonucleotide	O
probe	O
was	O
observed	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
These	O
data	O
suggest	O
that	O
the	O
IL-2	B-protein
and	O
CD3	O
signaling	O
pathways	O
provide	O
a	O
necessary	O
and	O
co-operative	O
stimulus	O
promoting	O
phosphorylation	O
of	O
CREB	B-protein
following	O
receptor	O
cross-linking	O
.	O
HIV-1	O
infection	O
induces	O
a	O
selective	O
reduction	O
in	O
STAT5	B-protein
protein	I-protein
expression	O
.	O
HIV-1	O
infection	O
is	O
accompanied	O
by	O
qualitative	O
and	O
quantitative	O
defects	O
in	O
CD4+	O
T	O
lymphocytes	O
.	O
Loss	O
of	O
immune	O
function	O
in	O
HIV	O
patients	O
is	O
usually	O
associated	O
with	O
a	O
profound	O
dysregulation	O
of	O
cytokine	O
production	O
.	O
To	O
investigate	O
whether	O
cytokine	O
signaling	O
defects	O
occur	O
during	O
HIV	O
infection	O
,	O
PHA	O
blasts	O
from	O
healthy	O
human	O
donors	O
were	O
infected	O
with	O
two	O
strains	O
of	O
HIV-1	O
and	O
screened	O
for	O
the	O
expression	O
of	O
STAT	B-protein
proteins	I-protein
used	O
in	O
cytokine	O
signaling	O
.	O
A	O
selective	O
decrease	O
in	O
STAT5B	B-protein
was	O
seen	O
8	O
days	O
after	O
infection	O
with	O
the	O
BZ167	O
dual-tropic	O
HIV	O
isolate	O
,	O
but	O
not	O
with	O
the	O
Ba-L	O
,	O
M-tropic	O
strain	O
.	O
Based	O
on	O
these	O
findings	O
,	O
purified	O
T	O
cells	O
from	O
HIV-infected	O
patients	O
in	O
different	O
stages	O
of	O
disease	O
were	O
also	O
tested	O
for	O
STAT	B-protein
expression	O
;	O
decreases	O
in	O
STAT5A	B-protein
,	O
STAT5B	B-protein
,	O
and	O
STAT1alpha	O
were	O
observed	O
in	O
all	O
patients	O
.	O
The	O
reduction	O
in	O
STATs	O
seen	O
in	O
vivo	O
and	O
in	O
vitro	O
after	O
HIV	O
infection	O
may	O
contribute	O
to	O
the	O
loss	O
of	O
T	O
cell	O
function	O
in	O
HIV	O
disease	O
.	O
Transcription	B-protein
factors	I-protein
that	O
regulate	O
monocyte	O
/	O
macrophage	O
differentiation	O
.	O
Although	O
all	O
the	O
cells	O
in	O
an	O
organism	O
contain	O
the	O
same	O
genetic	O
information	O
,	O
differences	O
in	O
the	O
cell	O
phenotype	O
arise	O
from	O
the	O
expression	O
of	O
lineage-specific	O
genes	O
.	O
During	O
myelopoiesis	O
,	O
external	O
differentiating	O
signals	O
regulate	O
the	O
expression	O
of	O
a	O
set	O
of	O
transcription	B-protein
factors	I-protein
.	O
The	O
combined	O
action	O
of	O
these	O
transcription	B-protein
factors	I-protein
subsequently	O
determines	O
the	O
expression	O
of	O
myeloid-specific	O
genes	O
and	O
the	O
generation	O
of	O
monocytes	O
and	O
macrophages	O
.	O
In	O
particular	O
,	O
the	O
transcription	B-protein
factor	I-protein
PU.1	I-protein
has	O
a	O
critical	O
role	O
in	O
this	O
process	O
.	O
We	O
review	O
the	O
contribution	O
of	O
several	O
transcription	B-protein
factors	I-protein
to	O
the	O
control	O
of	O
macrophage	O
development	O
Transcription	B-protein
factor	I-protein
LKLF	I-protein
is	O
sufficient	O
to	O
program	O
T	O
cell	O
quiescence	O
via	O
a	O
c-Myc	O
--	O
dependent	O
pathway	O
.	O
T	O
lymphocytes	O
circulate	O
in	O
a	O
quiescent	O
state	O
until	O
they	O
encounter	O
cognate	O
antigen	O
bound	O
to	O
the	O
surface	O
of	O
an	O
antigen-presenting	O
cell	O
.	O
The	O
molecular	O
pathways	O
that	O
regulate	O
T	O
cell	O
quiescence	O
remain	O
largely	O
unknown	O
.	O
Here	O
we	O
show	O
that	O
forced	O
expression	O
of	O
the	O
lung	B-protein
Kruppel-like	I-protein
transcription	I-protein
factor	I-protein
(	O
LKLF	O
)	O
in	O
Jurkat	O
T	O
cells	O
is	O
sufficient	O
to	O
program	O
a	O
quiescent	O
phenotype	O
characterized	O
by	O
decreased	O
proliferation	O
,	O
reduced	O
cell	O
size	O
and	O
protein	O
synthesis	O
and	O
decreased	O
surface	O
expression	O
of	O
activation	O
markers	O
.	O
Conversely	O
,	O
LKLF-deficient	O
peripheral	O
T	O
cells	O
produced	O
by	O
gene	O
targeting	O
showed	O
increased	O
proliferation	O
,	O
increased	O
cell	O
size	O
and	O
enhanced	O
expression	O
of	O
surface	O
activation	O
markers	O
in	O
vivo	O
.	O
LKLF	O
appeared	O
to	O
function	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
decreasing	O
expression	O
of	O
the	O
proto-oncogene	O
encoding	O
c-Myc	O
.	O
Forced	O
expression	O
of	O
LKLF	O
was	O
associated	O
with	O
markedly	O
decreased	O
c-Myc	O
expression	O
.	O
In	O
addition	O
,	O
many	O
effects	O
of	O
LKLF	O
expression	O
were	O
mimicked	O
by	O
expression	O
of	O
the	O
dominant-negative	O
MadMyc	O
protein	O
and	O
rescued	O
by	O
overexpression	O
of	O
c-Myc	O
.	O
Thus	O
,	O
LKLF	B-protein
is	O
both	O
necessary	O
and	O
sufficient	O
to	O
program	O
quiescence	O
in	O
T	O
cells	O
and	O
functions	O
,	O
in	O
part	O
,	O
by	O
negatively	O
regulating	O
a	O
c-Myc	O
--	O
dependent	O
pathway	O
.	O
HTLV-1	O
p12	O
(	O
I	B-protein
)	I-protein
protein	I-protein
enhances	O
STAT5	O
activation	O
and	O
decreases	O
the	O
interleukin-2	O
requirement	O
for	O
proliferation	O
of	O
primary	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
The	O
p12	O
(	O
I	B-protein
)	I-protein
protein	I-protein
,	O
encoded	O
by	O
the	O
pX	O
open	O
reading	O
frame	O
I	O
of	O
the	O
human	O
T-lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
,	O
is	O
a	O
hydrophobic	B-protein
protein	I-protein
that	O
localizes	O
to	O
the	O
endoplasmic	O
reticulum	O
and	O
the	O
Golgi	O
.	O
Although	O
p12	O
(	O
I	O
)	O
contains	O
4	O
minimal	O
proline-rich	O
,	O
src	O
homology	O
3-binding	O
motifs	O
(	O
PXXP	O
)	O
,	O
a	O
characteristic	O
commonly	O
found	O
in	O
proteins	O
involved	O
in	O
signaling	O
pathways	O
,	O
it	O
has	O
not	O
been	O
known	O
whether	O
p12	O
(	O
I	O
)	O
has	O
a	O
role	O
in	O
modulating	O
intracellular	O
signaling	O
pathways	O
.	O
This	O
study	O
demonstrated	O
that	O
p12	O
(	O
I	O
)	O
binds	O
to	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
the	O
interleukin-2	B-protein
receptor	I-protein
(	O
IL-2R	B-protein
)	I-protein
beta	I-protein
chain	I-protein
that	O
is	O
involved	O
in	O
the	O
recruitment	O
of	O
the	O
Jak1	B-protein
and	O
Jak3	B-protein
kinases	I-protein
.	O
As	O
a	O
result	O
of	O
this	O
interaction	O
,	O
p12	O
(	O
I	O
)	O
increases	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
5	I-protein
(	O
STAT5	B-protein
)	O
DNA	O
binding	O
and	O
transcriptional	O
activity	O
and	O
this	O
effect	O
depends	O
on	O
the	O
presence	O
of	O
both	O
IL-2R	B-protein
beta	I-protein
and	I-protein
gamma	I-protein
(	I-protein
c	I-protein
)	I-protein
chains	I-protein
and	O
Jak3	B-protein
.	O
Transduction	O
of	O
primary	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
with	O
a	O
human	O
immunodeficiency	O
virus	O
type	O
1-based	O
retroviral	O
vector	O
expressing	O
p12	O
(	O
I	O
)	O
also	O
resulted	O
in	O
increased	O
STAT5	O
phosphorylation	O
and	O
DNA	O
binding	O
.	O
However	O
,	O
p12	O
(	O
I	O
)	O
could	O
increase	O
proliferation	O
of	O
human	O
PBMCs	O
only	O
after	O
stimulation	O
of	O
T-cell	B-protein
receptors	I-protein
by	O
treatment	O
of	O
cells	O
with	O
low	O
concentrations	O
of	O
alphaCD3	O
and	O
alphaCD28	B-protein
antibodies	I-protein
.	O
In	O
addition	O
,	O
the	O
proliferative	O
advantage	O
of	O
p12	O
(	O
I	O
)	O
-transduced	O
PBMCs	O
was	O
evident	O
mainly	O
at	O
low	O
concentrations	O
of	O
IL-2	B-protein
.	O
Together	O
,	O
these	O
data	O
indicate	O
that	O
p12	O
(	O
I	O
)	O
may	O
confer	O
a	O
proliferative	O
advantage	O
on	O
HTLV-1-infected	O
cells	O
in	O
the	O
presence	O
of	O
suboptimal	O
antigen	O
stimulation	O
and	O
that	O
this	O
event	O
may	O
account	O
for	O
the	O
clonal	O
proliferation	O
of	O
infected	O
T	O
cells	O
in	O
vivo	O
.	O
(	O
2001	O
;	O
98	O
:	O
823-829	O
)	O
Single	O
dose	O
intranasal	O
administration	O
of	O
retinal	O
autoantigen	O
generates	O
a	O
rapid	O
accumulation	O
and	O
cell	O
activation	O
in	O
draining	O
lymph	O
node	O
and	O
spleen	O
:	O
implications	O
for	O
tolerance	O
therapy	O
.	O
BACKGROUND/AIMS	O
:	O
A	O
single	O
intranasal	O
delivery	O
of	O
retinal	O
autoantigen	O
suppresses	O
effectively	O
experimental	O
autoimmune	O
uveoretinitis	O
(	O
EAU	O
)	O
.	O
To	O
further	O
unravel	O
underlying	O
mechanisms	O
the	O
authors	O
wished	O
to	O
determine	O
,	O
firstly	O
,	O
the	O
kinetics	O
of	O
antigen	O
delivery	O
and	O
,	O
secondly	O
,	O
the	O
early	O
cellular	O
responses	O
involved	O
in	O
the	O
initial	O
stages	O
of	O
nasal	O
mucosal	O
tolerance	O
induction	O
.	O
METHODS	O
:	O
Flow	O
cytometry	O
,	O
cell	O
proliferation	O
assays	O
,	O
and	O
microscopy	O
were	O
used	O
to	O
track	O
antigen	O
following	O
a	O
single	O
,	O
intranasal	O
dose	O
of	O
Alexa-488	O
labelled	O
retinal	O
antigen	O
.	O
RESULTS	O
:	O
A	O
rapid	O
accumulation	O
of	O
antigen	O
within	O
both	O
superficial	O
cervical	O
lymph	O
nodes	O
(	O
SCLN	O
)	O
and	O
spleen	O
was	O
observed	O
after	O
30	O
minutes	O
.	O
Significant	O
proliferative	O
responses	O
to	O
IRBP	O
were	O
elicited	O
by	O
48	O
hours	O
indicating	O
that	O
systemic	O
priming	O
of	O
naive	O
T	O
cells	O
to	O
retinal	O
antigen	O
had	O
occurred	O
.	O
Cell	O
activation	O
was	O
further	O
confirmed	O
by	O
immunoprecipitation	O
studies	O
,	O
which	O
demonstrated	O
phosphorylation	O
of	O
STAT4	B-protein
but	O
not	O
STAT6	B-protein
in	O
both	O
lymph	O
nodes	O
and	O
spleen	O
.	O
However	O
,	O
at	O
24	O
hours	O
,	O
STAT4	O
heterodimerisation	O
with	O
STAT	O
3	O
was	O
only	O
observed	O
in	O
spleen	O
.	O
CONCLUSIONS	O
:	O
The	O
results	O
provide	O
novel	O
evidence	O
that	O
following	O
a	O
single	O
intranasal	O
application	O
rapid	O
transfer	O
of	O
antigen	O
occurs	O
.	O
Resulting	O
T	O
cell	O
proliferation	O
develops	O
consequent	O
to	O
differential	O
cell	O
signalling	O
in	O
SCLN	O
and	O
spleen	O
.	O
Further	O
understanding	O
of	O
these	O
underlying	O
cellular	O
mechanisms	O
,	O
in	O
particular	O
as	O
is	O
inferred	O
by	O
the	O
results	O
the	O
contribution	O
of	O
local	O
versus	O
systemic	O
tolerance	O
induction	O
,	O
may	O
assist	O
in	O
strategies	O
to	O
clinically	O
apply	O
mucosal	O
tolerance	O
therapy	O
successfully	O
.	O
Regulation	O
of	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-18	I-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
expression	O
on	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
during	O
T	O
helper	O
(	O
Th	O
)	O
1/Th2	O
differentiation	O
.	O
Critical	O
downregulatory	O
role	O
of	O
IL-4	B-protein
.	O
Interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-18	I-protein
has	O
been	O
well	O
characterized	O
as	O
a	O
costimulatory	B-protein
factor	I-protein
for	O
the	O
induction	O
of	O
IL-12-mediated	B-protein
interferon	I-protein
(	I-protein
IFN	I-protein
)	I-protein
-gamma	I-protein
production	O
by	O
T	O
helper	O
(	O
Th	O
)	O
1	O
cells	O
,	O
but	O
also	O
can	O
induce	O
IL-4	O
production	O
and	O
thus	O
facilitate	O
the	O
differentiation	O
of	O
Th2	O
cells	O
.	O
To	O
determine	O
the	O
mechanisms	O
by	O
which	O
IL-18	B-protein
might	O
regulate	O
these	O
diametrically	O
distinct	O
immune	O
responses	O
,	O
we	O
have	O
analyzed	O
the	O
role	O
of	O
cytokines	B-protein
in	O
the	O
regulation	O
of	O
IL-18	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
(	O
IL-18Ralpha	O
)	O
expression	O
.	O
The	O
majority	O
of	O
peripheral	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
constitutively	O
expressed	O
the	O
IL-18Ralpha	O
.	O
Upon	O
antigen	O
stimulation	O
in	O
the	O
presence	O
of	O
IL-12	B-protein
,	O
marked	O
enhancement	O
of	O
IL-18Ralpha	O
expression	O
was	O
observed	O
.	O
IL-12	B-protein
-mediated	O
upregulation	O
of	O
IL-18Ralpha	O
required	O
IFN-gamma	B-protein
.	O
Activated	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
that	O
expressed	O
low	O
levels	O
of	O
IL-18Ralpha	O
could	O
produce	O
IFN-gamma	B-protein
when	O
stimulated	O
with	O
the	O
combination	O
of	O
IL-12	B-protein
and	O
IL-18	B-protein
,	O
while	O
CD4	O
(	O
+	O
)	O
cells	O
which	O
expressed	O
high	O
levels	O
of	O
IL-18Ralpha	O
could	O
respond	O
to	O
IL-18	B-protein
alone	O
.	O
In	O
contrast	O
,	O
T	O
cell	O
stimulation	O
in	O
the	O
presence	O
of	O
IL-4	B-protein
resulted	O
in	O
a	O
downregulation	O
of	O
IL-18Ralpha	O
expression	O
.	O
Both	O
IL-4	B-protein
(	O
-/	O
)	O
-	O
and	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
Stat	I-protein
)	I-protein
6	I-protein
(	O
-/	O
)	O
-	O
T	O
cells	O
expressed	O
higher	O
levels	O
of	O
IL-18Ralpha	O
after	O
TCR	O
stimulation	O
.	O
Furthermore	O
,	O
activated	O
T	O
cells	O
from	O
Stat6	O
(	O
-/	O
)	O
-	O
mice	O
produced	O
more	O
IFN-gamma	O
in	O
response	O
to	O
IL-18	B-protein
than	O
wild-type	O
controls	O
.	O
Thus	O
,	O
positive/negative	O
regulation	O
of	O
the	O
IL-18Ralpha	O
by	O
the	O
major	B-protein
inductive	I-protein
cytokines	I-protein
(	O
IL-12	O
and	O
IL-4	B-protein
)	O
determines	O
the	O
capacity	O
of	O
IL-18	B-protein
to	O
polarize	O
an	O
immune	O
response	O
.	O
Glucocorticoid-regulated	B-protein
transcription	I-protein
factors	I-protein
.	O
Glucocorticoids	O
are	O
the	O
most	O
effective	O
antiinflammatory	O
drugs	O
used	O
in	O
the	O
treatment	O
of	O
asthma	O
.	O
They	O
act	O
by	O
binding	O
to	O
a	O
specific	O
receptor	O
(	O
GR	B-protein
)	O
that	O
,	O
upon	O
activation	O
,	O
translocates	O
to	O
the	O
nucleus	O
and	O
either	O
increases	O
(	O
transactivates	O
)	O
or	O
decreases	O
(	O
transrepresses	O
)	O
gene	O
expression	O
.	O
Inhibition	O
of	O
pro-inflammatory	B-protein
transcription	I-protein
factors	I-protein
such	O
as	O
activator	B-protein
protein	I-protein
(	O
AP	O
)	O
-1	O
,	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	O
transcription	O
(	O
STATs	B-protein
)	O
,	O
nuclear	B-protein
factor	I-protein
of	O
activated	O
T	O
cells	O
(	O
NFAT	B-protein
)	O
and	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
is	O
thought	O
to	O
be	O
a	O
major	O
action	O
of	O
glucocorticoids	O
.	O
Acetylation	O
of	O
histones	O
allows	O
unwinding	O
of	O
the	O
local	O
DNA	O
structure	O
and	O
enables	O
RNA	O
polymerase	O
II	O
to	O
enhance	O
gene	O
transcription	O
.	O
Histone	O
acetylation	O
is	O
regulated	O
by	O
a	O
balance	O
between	O
the	O
activity	O
of	O
histone	B-protein
acetyltransferases	I-protein
(	O
HATs	O
)	O
and	O
histone	O
deacetylases	O
(	O
HDACs	O
)	O
.	O
GR	B-protein
acts	O
as	O
a	O
direct	O
inhibitor	O
of	O
NF-kappa	B-protein
B-induced	I-protein
HAT	I-protein
activity	O
and	O
also	O
by	O
recruiting	O
HDAC2	O
to	O
the	O
NF-kappa	B-protein
B/HAT	I-protein
complex	I-protein
.	O
A	O
sub-group	O
of	O
patients	O
with	O
glucocorticoid-insensitive	O
asthma	O
have	O
an	O
inability	O
to	O
induce	O
histone	O
acetylation	O
in	O
response	O
to	O
dexamethasone	O
suggesting	O
reduced	O
expression	O
of	O
a	O
GR-specific	O
HAT	O
.	O
This	O
suggests	O
that	O
pharmacological	O
manipulation	O
of	O
specific	O
histone	O
acetylation	O
status	O
is	O
a	O
potentially	O
useful	O
approach	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
.	O
Identification	O
of	O
the	O
precise	O
mechanism	O
by	O
which	O
activated	O
GR	B-protein
recruits	O
HDAC2	O
may	O
reveal	O
new	O
targets	O
for	O
the	O
development	O
of	O
drugs	O
that	O
may	O
dissociate	O
the	O
antiinflammatory	O
actions	O
of	O
glucocorticoids	O
from	O
their	O
side	O
effects	O
that	O
are	O
largely	O
due	O
to	O
gene	O
induction	O
.	O
Copyright	O
Academic	O
Press	O
.	O
Differential	O
ultraviolet-B-induced	O
immunomodulation	O
in	O
XPA	O
,	O
XPC	O
,	O
and	O
CSB	O
DNA	O
repair-deficient	O
mice	O
.	O
Ultraviolet	O
B	O
irradiation	O
has	O
serious	O
consequences	O
for	O
cellular	O
immunity	O
and	O
can	O
suppress	O
the	O
rejection	O
of	O
skin	O
tumors	O
and	O
the	O
resistance	O
to	O
infectious	O
diseases	O
.	O
DNA	O
damage	O
plays	O
a	O
crucial	O
role	O
in	O
these	O
immunomodulatory	O
effects	O
of	O
ultraviolet	O
B	O
,	O
as	O
impaired	O
repair	O
of	O
ultraviolet-B-induced	O
DNA	O
damage	O
has	O
been	O
shown	O
to	O
cause	O
suppression	O
of	O
cellular	O
immunity	O
.	O
Ultraviolet-B-induced	O
DNA	O
damage	O
is	O
repaired	O
by	O
the	O
nucleotide	O
excision	O
repair	O
mechanism	O
very	O
efficiently	O
.	O
Nucleotide	O
excision	O
repair	O
comprises	O
two	O
subpathways	O
:	O
transcription-coupled	O
and	O
global	O
genome	O
repair	O
.	O
In	O
this	O
study	O
the	O
immunologic	O
consequences	O
of	O
specific	O
nucleotide	O
excision	O
repair	O
defects	O
in	O
three	O
mouse	O
models	O
,	O
XPA	O
,	O
XPC	O
,	O
and	O
CSB	O
mutant	O
mice	O
,	O
were	O
investigated	O
.	O
XPA	O
mice	O
carry	O
a	O
total	O
nucleotide	O
excision	O
repair	O
defect	O
,	O
whereas	O
XPC	O
and	O
CSB	O
mice	O
only	O
lack	O
global	O
genome	O
and	O
transcription-coupled	O
nucleotide	O
excision	O
repair	O
,	O
respectively	O
.	O
Our	O
data	O
demonstrate	O
that	O
cellular	O
immune	O
parameters	O
in	O
XPA	O
,	O
XPC	O
,	O
and	O
CSB	O
mice	O
are	O
normal	O
compared	O
with	O
their	O
wild-type	O
(	O
control	O
)	O
littermates	O
.	O
This	O
may	O
indicate	O
that	O
the	O
reported	O
altered	O
cellular	O
responses	O
in	O
xeroderma	O
pigmentosum	O
patients	O
are	O
not	O
constitutive	O
but	O
could	O
be	O
due	O
to	O
external	B-protein
factors	I-protein
,	O
such	O
as	O
ultraviolet	O
B	O
.	O
Upon	O
exposure	O
to	O
ultraviolet	O
B	O
,	O
only	O
XPA	O
mice	O
are	O
very	O
sensitive	O
to	O
ultraviolet-B-induced	O
inhibition	O
of	O
Th1-mediated	O
contact	O
hypersensitivity	O
responses	O
and	O
interferon-gamma	B-protein
production	O
in	O
skin	O
draining	O
lymph	O
nodes	O
.	O
Lipopolysaccharide-stimulated	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
and	O
interleukin-10	O
production	O
are	O
significantly	O
augmented	O
in	O
both	O
XPA	O
and	O
CSB	O
mice	O
after	O
ultraviolet	O
B	O
exposure	O
.	O
Lymph	O
node	O
cell	O
numbers	O
were	O
increased	O
very	O
significantly	O
in	O
XPA	O
,	O
mildly	O
increased	O
in	O
CSB	O
,	O
and	O
not	O
in	O
XPC	O
mice	O
.	O
In	O
general	O
XPC	O
mice	O
do	O
not	O
exhibit	O
any	O
indication	O
of	O
enhanced	O
ultraviolet	O
B	O
susceptibility	O
with	O
regard	O
to	O
the	O
immune	O
parameters	O
analyzed	O
.	O
These	O
data	O
suggest	O
that	O
both	O
global	O
genome	O
repair	O
and	O
transcription-coupled	O
repair	O
are	O
needed	O
to	O
prevent	O
immunomodulation	O
by	O
ultraviolet	O
B	O
,	O
whereas	O
transcription-coupled	O
repair	O
is	O
the	O
major	O
DNA	O
repair	O
subpathway	O
of	O
nucleotide	O
excision	O
repair	O
that	O
prevents	O
the	O
acute	O
ultraviolet-B-induced	O
effects	O
such	O
as	O
erythema	O
.	O
Biomechanical	O
strain	O
induces	O
class	O
a	O
scavenger	B-protein
receptor	I-protein
expression	O
in	O
human	O
monocyte/macrophages	O
and	O
THP-1	O
cells	O
:	O
a	O
potential	O
mechanism	O
of	O
increased	O
atherosclerosis	O
in	O
hypertension	O
.	O
BACKGROUND	O
:	O
Although	O
hypertension	O
is	O
an	O
important	O
risk	O
factor	O
for	O
the	O
development	O
of	O
atherosclerosis	O
,	O
the	O
mechanisms	O
for	O
this	O
interaction	O
are	O
incompletely	O
described	O
.	O
Previous	O
studies	O
have	O
suggested	O
that	O
biomechanical	O
strain	O
regulates	O
macrophage	O
phenotype	O
.	O
We	O
tested	O
the	O
hypothesis	O
that	O
biomechanical	O
strain	O
can	O
induce	O
expression	O
of	O
the	O
class	B-protein
A	I-protein
scavenger	I-protein
receptor	I-protein
(	O
SRA	O
)	O
,	O
an	O
important	O
lipoprotein	O
receptor	O
in	O
atherogenesis	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
Human	O
monocyte/macrophages	O
or	O
THP-1	O
cells	O
were	O
cultured	O
in	O
a	O
device	O
that	O
imposes	O
uniform	O
biaxial	O
cyclic	O
1-Hz	O
strains	O
of	O
0	O
%	O
,	O
1	O
%	O
,	O
2	O
%	O
,	O
or	O
3	O
%	O
,	O
and	O
SRA	O
expression	O
was	O
analyzed	O
.	O
Mechanical	O
strains	O
induced	O
SRA	O
mRNA	O
(	O
3.5+/-0.6-fold	O
at	O
3	O
%	O
strain	O
for	O
48	O
hours	O
,	O
P	O
<	O
0.01	O
)	O
and	O
SRA	B-protein
protein	I-protein
in	O
THP-1	O
cells	O
in	O
an	O
amplitude-dependent	O
manner	O
.	O
This	O
induction	O
was	O
accompanied	O
by	O
augmented	O
expression	O
of	O
the	O
class	O
B	O
scavenger	O
receptor	O
CD36	O
(	O
2.8+/-0.3-fold	O
,	O
P	O
<	O
0.001	O
)	O
but	O
not	O
by	O
increased	O
peroxisome	O
proliferator-activated	O
receptor-gamma	O
expression	O
.	O
To	O
evaluate	O
this	O
effect	O
in	O
vivo	O
,	O
apolipoprotein	O
E	O
(	O
-/-	O
)	O
mice	O
were	O
randomly	O
assigned	O
to	O
receive	O
standard	O
chow	O
,	O
a	O
high-cholesterol	O
diet	O
,	O
or	O
a	O
high-cholesterol	O
diet	O
with	O
hypertension	O
induced	O
by	O
angiotensin	B-protein
II	I-protein
infusion	O
for	O
8	O
weeks	O
.	O
Immunohistochemistry	O
revealed	O
that	O
among	O
macrophages	O
in	O
atherosclerotic	O
lesions	O
of	O
the	O
aorta	O
,	O
the	O
proportion	O
of	O
macrophages	O
with	O
SRA	O
expression	O
was	O
highest	O
in	O
hypertensive	O
animals	O
on	O
a	O
high-cholesterol	O
diet	O
(	O
43.9+/-0.7	O
%	O
,	O
versus	O
12.0+/-2.0	O
%	O
for	O
normotensive	O
animals	O
on	O
a	O
high-cholesterol	O
diet	O
and	O
4.7+/-4.7	O
%	O
for	O
animals	O
on	O
standard	O
chow	O
;	O
P	O
<	O
0.001	O
)	O
.	O
CONCLUSIONS	O
:	O
Biomechanical	O
strain	O
induces	O
SRA	O
expression	O
by	O
monocyte/macrophages	O
,	O
suggesting	O
a	O
novel	O
mechanism	O
for	O
promotion	O
of	O
atherosclerosis	O
in	O
hypertensive	O
patients	O
.	O
High	O
glucose	O
induces	O
MCP-1	B-protein
expression	O
partly	O
via	O
tyrosine	O
kinase-AP-1	O
pathway	O
in	O
peritoneal	O
mesothelial	O
cells	O
.	O
BACKGROUND	O
:	O
High	O
glucose	O
in	O
peritoneal	O
dialysis	O
solutions	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
peritoneal	O
fibrosis	O
in	O
chronic	O
ambulatory	O
peritoneal	O
dialysis	O
(	O
CAPD	O
)	O
patients	O
.	O
However	O
,	O
the	O
mechanisms	O
are	O
not	O
very	O
clear	O
.	O
Peritoneal	O
macrophages	O
seem	O
to	O
participate	O
in	O
the	O
process	O
of	O
peritoneal	O
fibrosis	O
and	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
(	O
MCP-1	B-protein
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
recruitment	O
of	O
monocytes	O
toward	O
the	O
peritoneal	O
cavity	O
.	O
However	O
,	O
little	O
is	O
known	O
about	O
the	O
effect	O
of	O
high	O
glucose	O
on	O
MCP-1	B-protein
expression	O
and	O
its	O
signal	O
transduction	O
pathway	O
in	O
human	O
peritoneal	O
mesothelial	O
cells	O
.	O
METHODS	O
:	O
Mesothelial	O
cells	O
were	O
cultured	O
with	O
glucose	O
(	O
5	O
to	O
100	O
mmol/L	O
)	O
or	O
mannitol	O
chronically	O
for	O
up	O
to	O
seven	O
days	O
.	O
MCP-1	B-protein
expression	O
of	O
mRNA	O
and	O
protein	O
was	O
measured	O
by	O
Northern	O
blot	O
analysis	O
and	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O
Chemotactic	O
activity	O
of	O
high-glucose-conditioned	O
culture	O
supernatant	O
was	O
measured	O
by	O
chemotactic	O
assay	O
.	O
To	O
examine	O
the	O
roles	O
of	O
the	O
transcription	B-protein
factors	I-protein
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
and	O
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
,	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
was	O
performed	O
.	O
RESULTS	O
:	O
Glucose	O
induced	O
MCP-1	O
mRNA	O
expression	O
in	O
a	O
time-	O
and	O
dose-dependent	O
manner	O
.	O
MCP-1	B-protein
protein	I-protein
in	O
cell	O
culture	O
supernant	O
was	O
also	O
increased	O
.	O
Equivalent	O
concentrations	O
of	O
mannitol	O
had	O
no	O
significant	O
effect	O
.	O
High-glucose-conditioned	O
supernatant	O
possessed	O
an	O
increased	O
chemotactic	O
activity	O
for	O
monocytes	O
,	O
which	O
was	O
neutralized	O
by	O
anti-MCP-1	B-protein
antibody	I-protein
.	O
EMSA	O
revealed	O
that	O
glucose	O
increased	O
the	O
AP-1	O
binding	O
activity	O
in	O
a	O
time-	O
and	O
dose-dependent	O
manner	O
,	O
but	O
not	O
NF-kappaB	B-protein
.	O
Curcumin	O
,	O
an	O
inhibitor	O
of	O
AP-1	B-protein
,	O
dose-dependently	O
suppressed	O
the	O
induction	O
of	O
MCP-1	O
mRNA	O
by	O
high	O
glucose	O
.	O
Tyrosine	O
kinase	O
inhibitors	O
such	O
as	O
genistein	O
(	O
12.5	O
to	O
50	O
micromol/L	O
)	O
and	O
herbimycin	O
A	O
(	O
0.1	O
to	O
1	O
micromol/L	O
)	O
inhibited	O
the	O
high-glucose-induced	O
MCP-1	O
mRNA	O
expression	O
in	O
a	O
dose-dependent	O
manner	O
,	O
and	O
also	O
suppressed	O
the	O
high-glucose-induced	O
AP-1	O
binding	O
activity	O
.	O
CONCLUSIONS	O
:	O
:	O
High	O
glucose	O
induced	O
mesothelial	O
MCP-1	B-protein
expression	O
partly	O
via	O
the	O
tyrosine	O
kinase-	O
AP-1	O
pathway	O
.	O
Signal	O
thresholds	O
and	O
modular	O
synergy	O
during	O
expression	O
of	O
costimulatory	B-protein
molecules	I-protein
in	O
B	O
lymphocytes	O
.	O
We	O
analyzed	O
intracellular	O
pathways	O
modulating	O
surface	O
densities	O
of	O
CD80	B-protein
and	O
CD86	B-protein
in	O
B	O
cells	O
activated	O
through	O
ligation	O
of	O
the	O
Ag	B-protein
receptor	I-protein
,	O
and	O
the	O
adhesion	B-protein
molecule	I-protein
CD54	I-protein
.	O
Whereas	B-protein
B	I-protein
cell	I-protein
Ag	I-protein
receptor	I-protein
(	O
BCR	B-protein
)	O
cross-linking	O
alone	O
stimulated	O
increased	O
expression	O
of	O
CD86	B-protein
,	O
up-regulation	O
of	O
CD80	B-protein
required	O
dual	O
stimulation	O
with	O
anti-IgM	O
and	O
anti-CD54	O
.	O
The	O
principal	O
downstream	O
component	O
contributed	O
by	O
BCR	B-protein
signaling	O
,	O
toward	O
both	O
CD80	B-protein
and	O
CD86	B-protein
induction	O
,	O
was	O
the	O
elevated	O
concentration	O
of	O
free	B-protein
cytoplasmic	I-protein
Ca	I-protein
(	O
2+	O
)	O
,	O
recruited	O
by	O
way	O
of	O
capacitative	O
influx	O
.	O
This	O
alone	O
was	O
sufficient	O
to	O
generate	O
an	O
increase	O
in	O
CD86	B-protein
levels	O
.	O
However	O
,	O
CD80	B-protein
enhancement	I-protein
required	O
the	O
concerted	O
action	O
of	O
both	O
intracellular	O
Ca	O
(	O
2+	O
)	O
concentration	O
and	O
CD54-initiated	O
pathways	O
.	O
The	O
nexus	O
between	O
anti-IgM	O
and	O
anti-CD54	O
stimulation	O
,	O
in	O
the	O
context	O
of	O
CD80	B-protein
regulation	O
,	O
was	O
identified	O
to	O
involve	O
a	O
self-propagating	O
process	O
of	O
sequential	O
synergy	O
.	O
The	O
first	O
step	O
involved	O
amplified	O
accumulation	O
of	O
intracellular	O
cAMP	O
,	O
as	O
a	O
result	O
of	O
cross-talk	O
between	O
BCR	B-protein
-mobilized	O
Ca	O
(	O
2+	O
)	O
and	O
CD54-derived	O
signals	O
.	O
This	O
then	O
facilitated	O
a	O
second	O
synergistic	O
interaction	O
between	O
Ca	O
(	O
2+	O
)	O
and	O
cAMP	O
,	O
culminating	O
in	O
CD80	B-protein
expression	O
.	O
Our	O
findings	O
of	O
distinct	O
signal	O
transducer	O
requirements	O
,	O
with	O
the	O
added	O
consequences	O
of	O
cross-talk	O
,	O
offers	O
an	O
explanation	O
for	O
variable	O
modulation	O
of	O
costimulatory	B-protein
molecule	I-protein
expression	O
in	O
response	O
to	O
diverse	O
physiological	O
stimuli	O
.	O
Importantly	O
,	O
these	O
results	O
also	O
reveal	O
how	O
concentration	O
threshold	O
barriers	O
for	O
recruitment	O
of	O
individual	O
second	O
messengers	O
can	O
be	O
overcome	O
by	O
constructive	O
convergence	O
of	O
signaling	O
modules	O
.	O
The	O
role	O
of	O
Epstein-Barr	O
virus	O
in	O
neoplastic	O
transformation	O
.	O
In	O
this	O
review	O
,	O
we	O
focus	O
on	O
new	O
data	O
from	O
basic	O
,	O
translational	O
and	O
clinical	O
research	O
relating	O
to	O
the	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
.	O
Beside	O
its	O
well-known	O
tropism	O
for	O
B	O
lymphocytes	O
and	O
epithelial	O
cells	O
,	O
EBV	O
also	O
infects	O
T	O
lymphocytes	O
,	O
monocytes	O
and	O
granulocytes	O
.	O
After	O
primary	O
infection	O
,	O
EBV	O
persists	O
throughout	O
the	O
life	O
span	O
in	O
resting	O
memory	O
B	O
cells	O
,	O
from	O
where	O
it	O
is	O
reactivated	O
upon	O
breakdown	O
of	O
cellular	O
immunity	O
.	O
In	O
the	O
process	O
of	O
neoplastic	O
transformation	O
,	O
the	O
EBV-encoded	B-protein
latent	I-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	O
LMP1	O
)	O
oncogene	O
represents	O
the	O
major	O
driving	O
force	O
.	O
LMP1	O
acts	O
like	O
a	O
constitutively	O
activated	O
receptor	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
family	I-protein
and	O
allows	O
the	O
amplification	O
or	O
bypassing	O
of	O
physiological	O
regulatory	O
signals	O
through	O
direct	O
and	O
indirect	O
interactions	O
with	O
proteins	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
factor	I-protein
(	I-protein
TRAF	I-protein
)	I-protein
family	I-protein
.	O
TRAF2	B-protein
-mediated	O
NF-kappaB	O
activation	O
,	O
AP-1	B-protein
induction	O
and	O
JAK3	B-protein
/	O
STAT	B-protein
activation	O
may	O
result	O
in	O
sustained	O
proliferation	O
leading	O
to	O
lymphoma	O
.	O
The	O
ability	O
of	O
LMP1	O
to	O
suppress	O
germinal	O
center	O
formation	O
and	O
its	O
capacity	O
to	O
mediate	O
its	O
own	O
transcriptional	O
activation	O
shed	O
new	O
light	O
on	O
the	O
pathogenesis	O
of	O
EBV-associated	O
latency	O
type	O
II	O
lymphoproliferations	O
like	O
Hodgkin	O
's	O
disease	O
and	O
angioimmunoblastic	O
lymphadenopathy	O
.	O
The	O
carboxy	O
terminus	O
of	O
LMP1	B-protein
is	O
also	O
a	O
reliable	O
marker	O
for	O
individual	O
EBV	O
strain	O
identification	O
and	O
thus	O
offers	O
new	O
possibilities	O
in	O
tracing	O
the	O
molecular	O
events	O
leading	O
to	O
posttransplant	O
lymphoproliferative	O
disorders	O
(	O
PTLDs	O
)	O
.	O
Cytotoxic	O
T	O
lymphocytes	O
directed	O
against	O
well-characterized	O
epitopes	O
of	O
EBV	O
latency	O
genes	O
represent	O
an	O
already	O
successful	O
and	O
promising	O
therapeutic	O
approach	O
to	O
EBV-associated	O
lymphomas	O
,	O
in	O
particular	O
PTLDs	O
Interferon-alpha	O
drives	O
T	O
cell-mediated	O
immunopathology	O
in	O
the	O
intestine	O
.	O
The	O
ability	O
of	O
interferon	B-protein
(	O
IFN	B-protein
)	O
-alpha	O
to	O
induce	O
autoimmunity	O
and	O
exacerbate	O
Th1	O
diseases	O
